Patent Grant
12106837
This document relates to systems and methods for the detection and resolution of occlusions in medication delivery devices. In some cases, the system can be adapted to use feedback from one or more sensors to detect an occlusion in a flow path from an automated medication delivery devices and, optionally, to determine how to resolve an occlusion. In some cases, methods, systems, and devices provided herein can use sensor information from occlusion detectors to determine an amount or timing of medication delivery.
Pump devices are commonly used to deliver one or more fluids to targeted individuals. In some cases, pump devices can receive feedback information from a patient to determine an amount of a fluid medication to administer to the patient. For example, an insulin infusion pump device may be used to deliver insulin to a person with diabetes (PWD) in order to control blood glucose levels and can receive information from a glucose sensor in order to determine an amount of insulin to be delivered. In use, however, occlusions can occur at either the infusion site or along the catheter (tubing) between the infusion pump and the infusion site, which can stop the delivery of medication until the occlusion is resolved. Some infusion pumps have incorporated sensors that can trigger an occlusion alarm if a threshold pressure is detected (see e.g., U.S. Pat. Nos. 8,409,142; 8,057,436; 7,892,199; 7,833,196; 7,828,528; 7,938,797; 8,808,230). Some occlusions may self-resolve overtime, after being jostled, or after sufficient pressure builds up, while other occlusions may require a user to change the infusion site or fix or change the catheter between the infusion pump and the infusion site. If an occlusion alarm triggers too early for back pressure that would have self-resolved, this can unnecessarily stress the user and potentially cause the user to experience alarm fatigue. On the other hand, significant delays in the delivery of insulin due to an occlusion can cause the PWD's blood glucose to rise, which may cause hyperglycemic events.
Methods, devices, and systems provided herein are adapted to safely and effectively provide automated medication delivery (preferably, automated medication delivery (AMD)) using based at least partially upon feedback from one or more occlusion sensors and (optionally) physiological feedback from the patient. In many circumstances, the methods, devices, and systems described herein provide an improvement in differentiating between the occlusions that require user intervention and those that do not, and to gain better information regarding whether insulin is actually being delivered to the PWD. In some cases, an occlusion sensor can be a pressure sensor in a medication reservoir or along a fluid flow path from the reservoir, or a force sensor used to detect a force of a mechanism used to apply pressure to a medication reservoir. In particular embodiments, AMD the devices, systems, and methods provided herein can be adapted to deliver insulin to a person with diabetes (PWD) based on feedback from a glucose sensor and feedback from an occlusion sensor.
In particular embodiments, devices, systems, and methods provided herein can determine or estimate an amount of medication stuck-in-transit (MST) and/or an amount of active medication on board (AMOB). In one example described below, an amount of AMOB can be estimated based on the amount of medication delivered and the time the medication was delivered using a decay curve for the medication. In some implementations, the amount of AMOB can be determined based on the amounts and timing of medication delivered, but subtracting an amount of MST determined based on back pressure detected by one or more occlusion or pressure sensors, with the MST being added back to AMOB once the back pressure resolves. Also, feedback information from one or more occlusion sensors can be correlated to amounts of MST. In some cases, the medication delivered can be insulin, and an amount of Insulin On Board (IOB) can be determined based on the timing of insulin deliveries made with an insulin infusion pump, but subtracting amounts of insulin detected as being insulin stuck-in-transit (IST) when an occlusion is detected due to pressure build up and adding it back if the pressure resolves without an infusion set change. Optionally, AMD systems, devices, and methods provided herein can determine an amount of additional medication to deliver based on AMOB while ignoring the MST. In particular embodiments, AMD systems, devices, and methods provided herein can determine whether a bolus of the MST and the additional medication is safe prior to delivering the additional amount of medication. For example, an automated insulin delivery (AID) system receiving feedback from a continuous glucose monitor (CGM) and an occlusion detector can use IOB, excluding any determined IST, to determine an amount of insulin to deliver assuming that the IST will remain constant (e.g., due to a slow release of insulin that releases pressure), but also determine if a bolus of the IST would be safe for the PWD if a temporary occlusion resolves upon that delivery of insulin. For example, methods, systems, and devices provided herein can determine if the delivery of the IST insulin, in addition to the determined amount, would likely send the PWD below a safe threshold blood glucose level. If determined to be safe, the additional insulin can be administered and the occlusion sensor monitored to see if the additional insulin causes the occlusion to resolve or if pressure continues to build, which can trigger an occlusion alarm by either causing the pressure/force to increase by a determined amount or to exceed a threshold. By delivering insulin assuming that IOB does not include the IST, the systems, methods, and devices provided herein can force an occlusion alarm to trigger more quickly if the occlusion is not self-resolving by delivering an additional dosage of insulin, but ensure safety by checking to see if the delivery of all the IST would be safe. In such cases, a determination that an amount of IST is unsafe may trigger an occlusion alarm or a message to the user that the user should disconnect an infusion set to prevent a full delivery of the IST. In some cases, a replacement of an infusion set can result in the IST being cleared from the system without being delivered to the user, thus methods, devices, and systems provided herein can have an IOB calculation that excludes undelivered IST from an IOB calculation, thus improving the accuracy of a control algorithm that uses IOB to determine insulin delivery rates.
In particular embodiments, methods, devices, and systems provided herein can detect an elevated pressure in a medication reservoir or in a delivery catheter and can determine a safe amount of additional medication that can be delivered to determine if the occlusion condition will self-resolve or not. Systems, devices, and methods provided herein can also issue an occlusion alarm if the additional medication is administered and the method, device, or system determines that the occlusion condition will not self-resolve. In some cases, methods, systems, and devices may provide troubleshooting instructions to the user in response to an occlusion alarm (e.g., instructions to check a catheter for kinks, to change the infusion site, to prime the catheter, etc.). In some implementations, methods, devices, and systems provided herein can estimate an amount of medicine that remains undelivered based on data from the occlusion detector. For example, a detected pressure in a catheter can be correlated to an amount of insulin that remains undelivered, which can depend on the length, rate of delivery, lumen thickness, and material of the catheter. As described herein, methods, devices, and systems can be adapted to deliver insulin to a PWD, and these systems can additionally receive blood glucose data from the PWD to determine an amount of insulin that can be delivered to the PWD safely without causing the PWD to experience hypoglycemia. For example, methods, systems, and devices provided herein may have an insulin sensitivity factor programmed in for a PWD and may have a current blood glucose level and optionally a current blood glucose trend, and may calculate a risk of a hypoglycemic event if an additional amount of insulin is administered to the user. In some implementations, methods, devices, and systems provided herein can provide users with non-disruptive tips on how to better use the system based on data from an occlusion sensor. For example, in some cases methods, systems, and devices provided herein can detect back pressure possibly due to hydrostatic pressure (i.e., pressure due to an altitude difference between the pump and an infusion site) and can provide the user with a notice that the pump should ideally be placed approximately at the same height as the infusion site.
Methods, systems, and devices provided herein can also adjust estimates of an amount of active medication remaining in a patient's body based on data from an occlusion sensor. For example, many medications have an active half-life after being administered to a patient, thus a determination or estimation of an amount of active medication in the user's body can be used to make future therapy decisions (either automatically or by the user). An occlusion condition, however, can delay when medication is actually delivered to the user. For example, pressure in a catheter can indicate that a certain volume of medication remains in the catheter, thus data from occlusion sensors can be used in methods, devices, and systems provided herein to produce a more accurate estimation of an amount of medication that remains active in a patient's body by not including medicine that remains in the catheter and/or by knowing when the medication was actually delivered to the user by tracking when the occlusion was resolved. In some cases, methods, systems, and devices provided herein can collect data regarding how an occlusion was resolved to make a determination of whether the medication was actually delivered. For example, methods, devices, and systems provided herein can use a troubleshooting tutorial to determine if that occlusion was resolved by removing the catheter from the infusion site or by replacing the infusion site, which would allow methods, systems, and devices provided herein to assume that the medication remaining in the catheter was not delivered. In some cases, methods, devices, and systems provided herein may make assumptions regarding the delivery of medication that maximize the safety of the patient. For example, if the data makes it unclear if a PWD received insulin, methods, devices, and systems provided herein may assume that that insulin was delivered in order to mitigate against the risk of a hypoglycemic event.
Methods, systems, and devices provided herein can also use pressure data or pressure proxy data (optionally from an occlusion detector) to detect possible disconnects from an infusion site. In particular embodiments, discrete pumping operations may cause a temporary pressure increase in the catheter during each pumping operation. In some cases, systems, methods, and devices provided herein can alarm if a pressure increase during a discrete pumping operation does not exceed a threshold. For example, a disconnected catheter may produce a small pressure rise. In some such situations, a larger pressure rise than normal might indicate that the infusion site may begin to occlude soon. In particular embodiments, the pressure spike profile for each discrete pumping operation may provide additional information about the infusion site (e.g., the location on the body, the age of the infusion site, whether medication is tunneling back towards the surface of the patient's skin). In some cases, methods, systems, and devices may alert the user against placing an infusion site at certain locations, about an upcoming need to change the infusion site, or to confirm that the catheter is properly secured to the infusion site.
Methods, systems, and devices provided herein can also use pressure data or pressure proxy data (optionally form an occlusion detector) to determine a relative position of the infusion site with respect to an infusion pump, which can be used to advise a user regarding an ideal relative positioning. An altitude difference between an infusion pump and an infusion site can result in hydrostatic pressure. If the pump is below the infusion site, the hydrostatic pressure increases the pressure detected in the catheter or reservoir. For example, a user sleeps in a bunkbed and places the pump on a night stand causing there to be a significant hydrostatic pressure. This hydrostatic pressure cause false occlusion alarms in systems that alarm immediately alarm immediately after any pressure is detected. Methods, devices, and systems provided herein, however, can observe detected pressures that remain approximately constant and determine that the pressure is due to a hydrostatic pressure and not an occlusion. If it is determined that a prolonged detected pressure is not an occlusion (due to an approximately steady state detected pressure), methods, devices, and systems provided herein can provide a non-disruptive tip or notice to a user explaining that an altitude difference was noticed for a prolonged period of time and/or telling the user to try to keep the pump at a height/altitude approximately the same as the infusion site. Additionally, if the infusion site is significantly below the pump and here is a particularly sensitive pressure sensor, a pressure rise during a pumping operation may not be as great as expected for the system, thus a troubleshooting evaluation questioning whether the infusion site is disconnected might also ask a user about the relative heights of the pump and infusion site.
In particular embodiments, methods, devices, and systems provided herein can automate the delivery of insulin to a person with diabetes (PWD) based on the PWD's blood glucose levels and/or occlusion detector data. In some cases, methods, devices, and systems provided herein can suspend, reduce, or increase an amount of basal insulin delivered to a PWD based on blood glucose data. Methods, devices, and systems provided herein can calculate an amount of active insulin in the PWD's body (e.g., calculate an IOB) based on deliveries of insulin to the PWD, using occlusion detector data to adjust the timing of insulin delivery based on any resolved occlusion conditions. In some implementations, an occlusion detector may require a threshold pressure in an insulin reservoir or in the infusion catheter before any back pressure will register, thus the detection of any back pressure may indicate that an amount of insulin thought to have been delivered was not delivered. Optionally, methods, devices, and systems can subtract an amount of insulin from the IOB upon an occlusion detector registering a threshold back pressure or registering any back pressure or methods, devices, and systems can trigger a delivery of a line-clearing bolus upon a determination that a first threshold occlusion condition is present and a determination that the delivery of the line-clearing bolus is safe for the PWD. For example, a safe line-clearing bolus can be based on the insulin sensitivity factor (ISF) of the PWD, the current blood glucose level of the user and optionally a blood glucose trend (e.g., from a continuous glucose monitor), an estimate of the IOB, and optionally projected blood glucose levels for the PWD based on said information. In some implementations, methods, devices, and systems provided herein can require an attempted delivery of a line-clearing bolus to determine if the occlusion condition is an occlusion that is likely to self-resolve prior to the issuance of an occlusion alarm. For example, if it is not safe to deliver the line-clearing bolus, it may indicate that the failure to deliver insulin is not yet dangerous to the PWD. In particular embodiments, an occlusion alarm threshold for an occlusion alarm may be lower than a threshold to deliver a line-clearing bolus. Methods, devices, and systems provided herein can monitor occlusion detector data during and after the delivery of a line-clearing bolus to determine if the additional insulin delivery further increases the back pressure in the insulin reservoir or infusion catheter or if it caused an occlusion condition to self-resolve. For example, if the pressure increases consistent with a full occlusion, this may trigger an occlusion alarm. In some cases, for example, a near zero change to the pressure detected after the line-clearing bolus may indicate that the detected pressure is possibly due to hydrostatic pressure, which may indicate that a disruptive alarm is not needed. Optionally, methods, devices, and systems provided herein may reduce future basal insulin deliveries to the PWD based on the delivery of the line-clearing bolus. For example, if the line-clearing bolus delivers 0.5 units of insulin, the basal insulin delivery may be delayed for a period of time during which that amount of insulin would have been delivered via the basal insulin delivery (e.g., the number of units delivered divided by the basal rate). In particular embodiments, methods, devices, and systems may only deliver line-clearing boluses when continuous blood glucose data is available and when basal insulin therapy is being actively automated.
Some embodiments of an infusion pump system may include one or more sensors for detecting a fluid pressure within an infusate flow pathway. The detected fluid pressures can be advantageously used by the infusion pump system in various ways. For example, in some embodiments, the detected fluid pressure can indicate when an occlusion exists in the infusate fluid pathway, and an alarm can alert the user to the presence of such an occlusion. In some embodiments, the detected fluid pressure can be used to determine an accurate time and amount of infusate delivered to the user. Such information can be used by the infusion pump system, for example, to accurately predict the user's future blood glucose levels. In some embodiments, the detected fluid pressure can be used to confirm whether a dispensation of infusate was actually delivered into the user's body (e.g., the user's vasculature).
Some or all of the embodiments described herein may provide one or more of the following advantages. First, the infusion pump system may include a pressure detection configuration that accurately detects occlusions in the infusate flow path extending from the pump device to the user. As such, the occlusion sensor feature can provide a notice (e.g., an alarm, an alert, etc.) to the user if he or she is receiving no dosage or a lower than desired dosage of infusate due to an occlusion in the infusate flow path. Such an occlusion may occur, for example, when the infusate fluid flow line (e.g., a cannula, infusion set tubing, or the like) is kinked.
Second, some embodiments of the infusion pump system may include a pressure detection configuration that can be used to determine an accurate time and an accurate amount of infusate actually delivered to the user. In some implementations, an occlusion in the infusate pathway is a transient occlusion. That is, for example, an occlusion may exist at the time of an infusate delivery, but later the occlusion may become fully or partially eliminated. In such a case, a desired dispensation of an amount of infusate may initially be either fully or partially reduced, and at a time thereafter the residual pressurized infusate in the pathway may be subsequently delivered to the user when the occlusion is eliminated. The pressure detection configuration can thereby be used to detect the actual amounts and the actual times at which both the initial and the subsequent infusate deliveries are made. Such information can be advantageously used by the infusion pump system for various purposes. For example, such information can be used to accurately predict the user's future blood glucose levels (e.g., when insulin is the infusate), which can be used in a control algorithm used to automate infusate delivery.
Third, some embodiments of the infusion pump system may include an analyte sensor. In some cases, the analyte can be used to determine an alarm threshold for triggering an occlusion alarm. For example, when insulin is the infusate, a rising blood glucose level can indicate the possibility of a new occlusion, thus a rising blood glucose trend may indicate a higher probability of an occlusion, thus an alarm threshold can be lowered so that an occlusion alarm is triggered sooner. If a PWD's blood glucose level is steady at a target level or within a target range, however, it may not be necessary to trigger an occlusion alarm as quickly if the occlusion may self-resolve. Optionally, rather than merely changing the alarm threshold for an occlusion alarm, analyte sensor data can be used to determine if an additional administration of infusate is safe. For example, if insulin is the infusate and the user is a PWD, then analyte sensor data can be used to determine if the administration of an additional dose of insulin is safe for the PWD based on the PWD's insulin sensitivity factor (ISF) and an amount of insulin stuck-in-transit (IST). For example, if an insulin pump is determined to have a back pressure corresponding to 0.5 units of IST, that can be used to determine if that IST plus an additional administration of 0.2 units is likely to send the user into a hypoglycemic condition. If it is determined to be safe, it can be delivered to see if the pressure continues to increase in a way consistent with a non-resolving occlusion. In some cases, the additional administration can be designed to send the back pressure to an amount above an occlusion alarm threshold if the additional administration does not cause the occlusion to resolve. In particular embodiments, methods, systems, and devices provided herein can evaluate a pressure increase after the additional administration to evaluate if the increase is consistent with a non-self-resolving occlusion. In some implementations, data from an analyte sensor can be used in the automation of infusate delivery, but the pressure sensor can be used to stop the automatic delivery of extra infusate above a baseline amount when an occlusion is suspected. For example, when insulin is the infusate, data from a continuous glucose monitor (CGM) for a PWD can be used to stop insulin delivery, methods, devices, and systems provided herein that can deliver insulin at a preprogrammed basal rate, at one or more larger rates, and optionally at one or more lower rates (which can be a rate of zero). In some cases, such methods, devices, and systems can prevent the delivery of the one or more larger rates of insulin delivery when a pressure sensor indicates a possible occlusion or a significant amount of IST, even before an occlusion alarm is triggered, which can prevent an amount of IST from becoming too large prior to an occlusion self-resolving. In these cases, additional insulin deliveries can be used during this period of time to test whether the occlusion condition is likely to self-resolve to determine whether to sound an occlusion alarm.
Third, some embodiments of the infusion pump system may include a pressure detection configuration that can be used to indicate whether a dispensation of infusate was actually delivered into the user's body (e.g., into the user's vasculature). For example, when an infusate is being dispensed into the user's body, the pressure in the infusate pathway will expectantly increase because of back pressure associated with the user's body. If, however, the infusate fluid flow line is not coupled to the user at the time of the infusate dispensation, no such back pressure will be present, and the pressure in the infusate pathway will therefore be less than expected. When a lower than expected infusate pathway pressure is detected during an infusate dispensation, the infusion pump system may ascertain that no infusate was delivered to the user because the infusate fluid flow line was not coupled to the user. In some cases, appropriate countermeasures can then be initiated by the infusion pump system, such as an alert or alarm to the user to prompt the user to properly install the infusate fluid flow line.
Fourth, some embodiments of the infusion pump system may be configured to be portable, wearable, and (in some circumstances) concealable. For example, a user can conveniently wear the infusion pump system on the user's skin under clothing or can carry the pump device in the user's pocket (or other portable location) while receiving the medicine dispensed from the pump device.
Thus, the embodiments described herein provide the benefit of a medicine delivery system that can better differentiate between occlusions that require user intervention and those that do not, and allowing users to gain better information regarding whether insulin is actually being delivered to the PWD.
Medication delivery methods, devices, and systems provided herein can use occlusion sensor data to more quickly and/or more accurately identify occlusions, to improve the automation of medication delivery, use analyte data to improve the accuracy and timing of occlusion alarms, and can detect disconnected infusion sets. In some cases, methods, devices, and systems provided herein can use occlusion sensor data to distinguish between AMOB and medication stuck-in-transit (MST), which can be used to improve the automation of medication delivery. In particular embodiments, the medication delivery methods, devices, and systems, can be insulin delivery methods, devices, and systems. In some cases, methods, devices, and systems provided herein can be Automated Insulin Delivery (AID) methods, devices, and systems.
Additional details about DMS 10 is discussed below in reference to
Methods, systems, and devices provided herein can use non-binary data from an occlusion sensor, which can be a pressure sensor or a force sensor, to more quickly identify occlusion condition in an infusion pump that require user intervention, to minimize alarms issued for self-resolving occlusion conditions, and to optionally trigger administrations of medication designed to safely test whether a non-self-resolving occlusion condition exists. Additionally, methods, systems, and devices provided herein can use non-binary data from an occlusion detector to improve the automation of medication delivery by having more accurate information about an amount of active medication on board (AMOB) by knowing an amount of medication stuck-in-transit (MST).
Determining when Medication has been Delivered
Methods, devices, and systems provided herein can use non-binary occlusion detector data to determine an amount of infusate on board or active medication on board (AMOB) by determining an amount of medication stuck-in-transit (MST). In some cases, the medication can be insulin, and methods, devices, and systems provided herein can determine an amount of Insulin-on-Board (IOB) or some other calculation of active insulin by determining an amount of Insulin Stuck-in-transit (IST). In describing these concepts, the description below references the charts of
Medications such as insulin typically have activity profiles which differ depending on the specific medication, and can depend on how it is delivered, the specific biochemistry of the patient, and other factors. AMOB is an estimation of how much active medication remains in the patient, and can be used to determine whether an additional administration of medication is safe and/or recommended. For example, IOB is a calculation of an amount of active insulin remaining in a person with diabetes (PWD), and can be used by the PWD to determine if the PWD should administer an additional bolus. In some cases, automated insulin delivery systems can monitor data from a glucose monitor and use that data along with a calculation of IOB to determine a subsequent insulin dosage (e.g., a bolus or a basal adjustment). Because an estimation of AMOB requires knowledge of when the medication was delivered, better data on when medication was delivered can produce more accurate estimations of an amount of AMOB. Accordingly, data from an occlusion detector can be used to determine an amount of MST.
Referring to
Referring to
Referring to
In some cases, these curves can depend on the material(s) and/or length(s) of the particular infusion catheter or infusion sets used, thus in some cases, methods, devices, and systems provided herein can use data about a particular infusion set or infusion catheter being used to make adjustments to the correlation between occlusion sensor data and a determined amount of MST. The detection limit of each sensor can be due to compliance in the sensor design.
Referring to
Method 400 begins at step 410 with the initiation of a dispensation of infusion fluid. For example, in some embodiments, step 410 can comprise an activation (by an infusion pump controller) of a drive system of the infusion pump with the purpose of dispensing a particular amount of infusate to the user of the infusion pump. In some examples, a particular number of units of infusate (e.g., the medication, which can be insulin) may be intended to be delivered to the user by virtue of the activation of the infusion pump drive system. The drive system of the infusion pump can be designed to dispense an accurately controlled amount of infusate. The controller of the infusion pump can initiate and control the activation of the pump drive system so that a targeted (intended) amount of infusate is dispensed as a result of the activation (assuming there are no unintended occlusions within the infusate flow path).
At step 420, the fluid pressure within the infusate flow pathway is detected by the controller of the infusion pump. The pressure detection may be performed using various devices and techniques, as described herein. In some cases, pressure signals are collected on a periodic basis (e.g., once per second, once per 5 seconds, once per 10 seconds, once per 20 seconds, once per 30 seconds, once per 45 seconds, once per minute, less frequently than once per minute, and the like, and within ranges thereof). In some cases, pressure signals may be collected multiple times during the actuation of the mechanical delivery to characterize the pressure profile during the delivery. Signals from pressure detectors can be sent to and received by a control circuitry of the infusion pump. The control circuitry can store the detected pressure signals in memory for analysis and processing. In some cases, the control circuitry stores a timestamp in association with the detected pressure signals. Hence, a time-based pressure profile of the fluid pressure within the infusate flow pathway can be created by the control circuitry. Such data can be further analyzed and processed by the control circuitry. For example, the data can be compared to threshold values, the data can be analyzed to identify times when changes in pressure occurred, the data can be analyzed to identify trends, and the like.
At step 430, the controller of the infusion pump determines the time and amount of infusate deliveries. The controller can use the pressure data collected in step 420 to perform step 430. As described further in the following example, using the pressure data collected in step 420 can, in some cases, enhance the accuracy of the determination of the time and amount of infusate deliveries (as compared to merely relying on the initiation of intended infusate deliveries from step 410). For example, an amount of MST can be determined based on a detected pressure or a pressure estimate based on a force sensor or other type of occlusion sensor, and the amount of MST can be excluded from a calculation of AMOB. Such accuracy enhancements can provide user advantages such as better management of blood glucose levels.
For example, the controller in step 430 can identify an occlusion in the infusate flow pathway by measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation. Additionally, fluid pressure within the infusate pathway can be due to hydrostatic pressure. Infusate dispensations (timing and amount) that are affected by partial occlusions, transient occlusions, and/or hydrostatic pressure can be identified by the controller by measuring and analyzing the fluid pressure within the infusate flow pathway after the pump drive mechanism is activated for such a dispensation. For example, in some cases a transient occlusion can reside in the infusate flow pathway. When a transient occlusion resides in the infusate flow pathway, an intended dispensation will be initially partially or fully prevented from actually reaching the user, but later (after the occlusion is obviated) the intended dispensation will be actually delivered. By measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation, the infusion pump control circuitry can identify the amount(s) and time(s) when the infusate was actually delivered to the user. Similarly, an altitude difference between the infusion pump and infusion site can result in back pressure and result in MST until the height difference is eliminated. Such information about MST can be advantageous, for example, to calculate the insulin-on-board for a user and in algorithms that use insulin-on-board as a parameter for managing the user's blood glucose level. Insulin-on-board is a term of art generally describing an amount of insulin that has been dosed to the user but whose blood glucose lowering effect has not yet occurred due to delayed action in the pharmacodynamics of subcutaneously infused insulin.
When a transient occlusion resides in the infusate flow pathway, a dispensation will cause the infusate pressure to rise and remain above the steady-state level for period of time that is longer than normal (here “normal” refers to the scenario with no unintended occlusions in the infusate flow pathway). Subsequently, at some time thereafter, the infusate pressure will reduce to the normal the steady-state level (indicating that the entire amount of infusate has then actually been delivered). By measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation, the control circuitry can identify such an occurrence and can ascertain the time(s) when the infusate was actually delivered.
In some cases, the lack of temporary back pressure during a pumping operation may indicate that an infusion set is disconnected and that the user is not receiving medication, or that the infusion site is much lower in altitude than the infusion pump. Typically, a dispensation of infusate will result in a short-lived rise in the fluid pressure within the infusate flow pathway. The rise will occur while the infusate is flowing from the infusion pump to the user. During such flows, the pressure will rise from a steady-state pressure level and then return to approximately the same steady-state pressure level when the dispensation has been completed. By measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation, if there is a pressure sensor sensitive enough to detect this temporary back pressure during a pumping operation, the infusion pump control circuitry can confirm that the intended amount of infusate was actually delivered to the user at the intended time. By extension, the control circuitry can also identify deviations from such intended infusate dispensations (timing and amount) by measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation, and query the user to check that the infusion site is properly installed and/or the relative heights of the infusion pump and the infusion site.
A repetitious loop can exist between steps 430 and 420. That is, pressure detection and pressure data analysis can be repeated again and again to ascertain accurate knowledge (by the infusion pump controller) of the timing and amounts of the actual deliveries of the infusate to the user.
In optional step 440, the controller can determine an amount of active medication on board (AMOB), which can also be referred to as infusate on board, using the information determined in previous step 430. This step is just one example of how the information determined in previous step 430 can be used in an advantageous manner. The effectiveness of blood glucose management by a closed-loop infusion pump system (and/or an open-loop system) is negatively affected when intended dispensations of insulin are not actually delivered to the user. Such a situation is exacerbated when the device or person(s) making decisions about the times and amounts of future dispensations of insulin is/are unaware of the discrepancies between the intended and actual dispensations. Hence, method 400 provides awareness of such discrepancies, and the awareness can be put to practical use here in step 440. For example, in the case of a transient occlusion as described above, some or all of the insulin dispensation was delayed (i.e., some or all of the insulin dispensation occurred later than at the intended time). As such, the user's blood glucose level may be above a targeted level for longer than expected (because the delayed insulin has not yet been metabolized). If the fact that the dispensation was merely delayed as a result of a transient occlusion is known by the decision-maker (either device or person(s)), the decision-maker will not “over-react” by initiating an unneeded or excessive dispensation to bring the blood glucose level down. Instead, the decision-maker will understand that the user has the insulin-on-board as needed to perhaps eventually bring the blood glucose level down to the targeted level.
Detecting Disconnected Infusion Set
In some cases, certain occlusion detectors with detection thresholds that permit the detection of transient pressure increases during the pumping of infusate or medication can be used to determine if an infusion set is disconnected to trigger an alarm. Referring to
Method 500 can be used to detect whether a dispensation of infusate was actually delivered into the user's body (e.g., subcutaneously). For example, when an infusate dispensation is being made into the user's body, the pressure in the infusate pathway will expectantly increase because of back pressure associated with the user's body. If, however, the infusate fluid flow line is not coupled to the user at the time of the infusate dispensation, no such back pressure will be present, and the pressure in the infusate pathway will therefore be less than expected. When a lower than expected infusate pathway pressure is detected during an infusate dispensation, the infusion pump system may ascertain that no infusate was delivered to the user because the infusate fluid flow line was not coupled to the user. In some cases, appropriate countermeasures can then be initiated by the infusion pump system, such as an alert or alarm to the user to prompt the user to properly install the infusate fluid flow line.
Method 500 begins at step 510 with the initiation of a dispensation of infusion fluid. For example, in some embodiments, step 510 can comprise an activation (by an infusion pump controller) of a drive system of the infusion pump with the purpose of dispensing a particular amount of infusate to the user of the infusion pump. In some examples, a particular number of units of insulin may be intended to be delivered to the user by virtue of the activation of the infusion pump drive system. The drive system of the infusion pump can be designed to dispense an accurately controlled amount of infusate. The controller of the infusion pump can initiate and control the activation of the pump drive system so that a targeted (intended) amount of infusate is dispensed as a result of the activation (assuming there are no unintended occlusions within the infusate flow path).
At step 520, the fluid pressure within the infusate flow pathway is detected by the controller of the infusion pump. The pressure detection may be performed using various devices and techniques, as described above. In some cases, pressure signals are collected on a periodic basis (e.g., between every discrete dispensing operation, once per second, once per 5 seconds, once per 10 seconds, once per 20 seconds, once per 30 seconds, once per 45 seconds, once per minute, less frequently than once per minute, and the like, and within ranges thereof). In some cases, pressure signals may be collected multiple times during the actuation of the mechanical delivery to characterize the pressure profile during the delivery. Signals from pressure detectors can be sent to and received by a control circuitry of the infusion pump. The control circuitry can store the detected pressure signals in memory for analysis and processing. In some cases, the control circuitry stores a timestamp in association with the detected pressure signals. Hence, a time-based pressure profile of the fluid pressure within the infusate flow pathway can be created by the control circuitry. Such data can be further analyzed and processed by the control circuitry. For example, the data can be compared to threshold values, the data can be analyzed to identify times when changes in pressure occurred, the data can be analyzed to identify trends, and the like.
When an infusion set is properly coupled to the user, a dispensation of infusate will result in a short-lived rise in the fluid pressure within the infusate flow pathway. The pressure rise will result because of back-pressure from the user's body (e.g., vasculature), and occur while the infusate is flowing from the infusion pump to the user. During such flows, the pressure will rise from a steady-state pressure level and then return to approximately the same steady-state pressure level when the dispensation has been completed. By measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation, the infusion pump control circuitry can confirm that the infusion set is coupled to the patient. By extension, the control circuitry can also identify deviations from such intended infusate dispensations by measuring and analyzing the fluid pressure within the infusate flow pathway during such a dispensation. The analysis of the pressure level during the actuation of the delivery may include characterizing any number of metrics such as the shape of the pressure profile during delivery, the maximum pressure level during delivery, the time to return to within some percentage of base pressure level, etc.
At step 530, the controller can determine whether the fluid pressure within the infusate flow pathway actually exhibited the aforementioned expected short-lived rise in the fluid pressure (which indicates that the infusion set is coupled to the user). If the infusion set is not coupled to the user, little back-pressure will exist and therefore the fluid pressure within the infusate flow pathway will not rise to the expected level during a dispensation. When such a scenario occurs, the controller can ascertain that the infusion set is not coupled to the user. Other measured metrics such as the shape of the pressure profile or the time to return to base pressure level may also be used to infer whether the infusion set is not coupled to the user.
A repetitious loop can exist between steps 530 and 510. That is, infusate dispensations and pressure data analysis can be repeated to ascertain accurate, ongoing knowledge (by the infusion pump controller) of whether the infusion set is coupled to the user.
At step 540, in response to an identification by the controller that the infusion set is not coupled to the user, the controller can initiate a notification to the user. Such a notification can be an alarm or alert of various types such as described above in regard to occlusion detection.
Timing Occlusion Alarms
In some cases, methods, devices, and systems provided herein can use different alarm thresholds for an occlusion detector based on data received from an analyte sensor. In some cases, methods, devices, and systems provided herein can use different alarm thresholds for an occlusion detector based on whether a bolus of medication has recently been delivered. In some cases, methods, devices, and systems provided herein can have an alarm threshold be adjusted based on the age of an infusion set. As such, the alarm thresholds in
In some cases, methods, devices, and systems provided herein can test a detected occlusion condition to determine if it is a self-resolvable occlusion condition and/or if it is the type of occlusion condition that requires user intervention. Accordingly, the test can determine if an occlusion alarm should be raised more quickly (e.g., if it requires user intervention) or if the alarm should be delayed in order to allow the occlusion condition to possibly self-resolve. In some cases, methods, devices, and systems provided herein can use analyte data to determine if the test is safe and/or whether it is safe to delay the alarm. In some cases, the test can include the administration of additional medication and an observation of occlusion sensor data to determine if a resulting increase in pressure (or force or change in light) indicates that the occlusion condition is complete and/or whether the occlusion condition is likely to self-resolve. For example, referring to
If the detected pressure (or detected light or force) is at or greater than the first threshold value, the processor detects whether the pressure is above a second alarm threshold value in step 640, which can be the alarm thresholds depicted in
If the detected pressure (or detected light or force) is less than the second alarm threshold value but above the first threshold value, then step 650 can determine if an additional administration of infusate is safe. This additional administration can be off schedule infusate delivery or delivery that is not based on the algorithm reference above for step 610. In some cases, the additional administration of infusate can be a minimum medication unit increment based on the infusion pump. In some cases, the additional administration of infusate can be an amount of medication calculated to result in a pressure exceeding the second alarm threshold value if the infusion pump is fully occluded. In some cases, the additional administration can be a maximum amount calculated to be safe according to a predictive algorithm, which may be limited to a maximum amount. For example, in the case of insulin being delivered using the pumps depicted in
If the additional administration in step 660 is not safe, then the procedure 600 can return to step 610 for the next administration of medication according a user request, to an algorithm, or according to a schedule.
If the additional administration is safe in step 660, additional infusate is delivered in step 670. In step 680, a pressure (or force or light) is detected again, and step 690 determines if the pressure rise (or lack thereof) is consistent with an occlusion. In some cases, step 680 can occur immediately after step 670. In some cases, step 680 can be delayed for a predetermined period of time after step 670. In some cases, the delay can be between 1 second and 5 minutes. In some cases, the delay can be at least 5 seconds, at least 10 seconds, at least 30 seconds, or at least 1 minute. In some cases, the delay can be less than 5 minutes, less than 3 minutes, or less than 2 minutes.
Step 690 can determine if the pressure increase is consistent with a non-self-resolving occlusion. In some cases, the additional delivery of infusate is calculated to be an amount likely to send the pressure above the second alarm threshold value and step 690 can merely detect whether the pressure (or force or light) detected in step 680 is at or above the second alarm threshold value. In some cases, step 690 can analyze a change in pressure (or light or force) to see if it is consistent with a curve indicating a total occlusion, such as example curves 810, 830, and 850 depicted in
Exemplary Medication Delivery System
Methods, devices, and systems provided herein can be used to deliver any suitable medication, and can include an infusion pump of any appropriate design that includes some sensor designed to detect an occlusion condition. In some cases, the occlusion sensor is a pressure sensor, a force sensor, or a sensor that is adapted to detect other changes to correlate to a pressure increase in a medication reservoir and/or an infusion catheter. In the examples discussed below, the methods, devices and systems are used to deliver insulin.
Referring back to
In some cases, an analyte sensor, such as continuous glucose monitor 50, can be used as part methods, systems, and devices provided herein to automate medication delivery, change occlusion alarm thresholds, and/or determine whether an additional delivery of medication is safe. As shown, insulin pump assembly 15 is in wireless communication with continuous glucose monitor 50 and data from continuous glucose monitor 50 can be transferred to the mobile computing device 60 via insulin pump assembly 15. In some cases, a blood glucose meter 70 can be in wireless communication with infusion pump assembly 15. Alternatively, other methods and paths of communication are contemplated, including wired communication. In some cases, a continuous glucose monitor 50 can be incorporated into a single unit with an infusion pump assembly.
In some embodiments, DMS 10 can be a closed-loop insulin delivery system that uses glucose data from continuous glucose monitor 50 and/or blood glucose monitor 70 in one or more feedback loops to change basal delivery rates, update parameters, settings, and/or models for dosage delivery that are specific to the user. In some cases, a pump controller (e.g., pump controller device 200) is part of pump assembly 15 and includes one or more processors adapted to alter basal delivery rates, change parameters, settings and/or models for dosage delivery based on glucose data from a continuous glucose monitor 50 and/or a blood glucose meter 70. In some cases, algorithms for changing basal delivery rates, update parameters, settings, and/or models for dosage delivery that are specific to the user can be present on mobile computing device 60 and/or on a remote server that is accessed by the mobile computing device 60 via the cloud.
Occlusion alarms or alerts discussed herein can be sounded using any suitable manner, which can include one or more of audible tones, haptic feedback, and/or visual indications, which can come from the pump assembly 15, mobile computing device 60, CGM 50, and/or BGM 70. In some cases, pump assembly 15 can include between one or more LED indicators adapted to light to inform the user of certain conditions, which can include an occlusion condition. In some cases, mobile computing device 60 can provide troubleshooting tips and/or instructions regarding how to resolve an occlusion if an occlusion alarm sounds. In some cases, the troubleshooting tips can include an audiovisual presentation illustrating one or more of (a) a depiction of how to check for kinks in an occlusion catheter; (b) checking the infusion site; (c) instruction to change the infusion set; and/or (d) questions about the last time the occlusion set was changed. Alternatively, the infusion pump assembly can include robust user interface that can provide the user with text instructions or suggestions regarding how to fix an occlusion.
In some cases, methods, systems, and devices provided herein can track when an infusion set was last changed and change alarm thresholds based on length of time that the infusion set has been used. In some cases, an infusion set age can be estimated based on actions that the user takes to prime the cannula of the infusion set (e.g., fill the infusion set catheter with infusate). In some cases, methods, devices, and systems provided herein can ask the user to input infusion set changes. Changing alarm thresholds based on infusion set age can improve user compliance with the labeled use of an infusion set. Additionally, non-self-resolving occlusions can become more common as an infusion set ages. In some cases, a troubleshooting guide provided to the user during/after an occlusion alarm can be different based on the age of an infusion set.
Mobile computing device 60 can be any of a variety of appropriate computing devices, such as a smartphone, a tablet computing device, a wearable computing device, a smartwatch, a fitness tracker, a laptop computer, a desktop computer, and/or other appropriate computing devices. In some cases, mobile computing device 60 can be used to transfer data from controller device 200 to the cloud. In some cases, the mobile computing device 60 provides a user interface (e.g., graphical user interface (GUI), speech-based user interface, motion-controlled user interface) through which users can provide information to control operation of the controller device 200 and the insulin delivery system 10. For example, the mobile computing device 60 can be a mobile computing device running a mobile app that communicates with the controller device 200 over short-range wireless connections (e.g., BLUETOOTH® connection, Wi-Fi Direct connection) to provide status information for the insulin delivery system 10 and to allow a user to control operation of the insulin delivery system 10 (e.g., toggle between delivery modes, adjust settings, log food intake, confirm/modify/cancel bolus dosages, and the like).
Continuous glucose monitor 50 can include a housing 52, a wireless communication device 54, and a sensor shaft 56. The wireless communication device 54 can be contained within the housing 52 and the sensor shaft 56 can extend outward from the housing 52. In use, the sensor shaft 56 can penetrate the skin 20 of a user to make measurements indicative of characteristics of the user's blood (e.g., the user's blood glucose level or the like). In some cases, the sensor shaft 56 can measure glucose or another analyte in interstitial fluid or in another fluid and correlate that to blood glucose levels. In response to the measurements made by the sensor shaft 56, continuous glucose monitor 50 can employ the wireless communication device 54 to transmit data to a corresponding wireless communication device 247 housed in the pump assembly 15. In some cases, the monitoring device 50 may include a circuit that permits sensor signals (e.g., data from the sensor shaft 56) to be communicated to the communication device 54. The communication device 54 can transfer the collected data to the controller device 200 (e.g., by wireless communication to the communication device 247). Alternatively, the monitoring device 50 can employ other methods of obtaining information indicative of a user's blood characteristics and transferring that information to the controller device 200. For example, an alternative monitoring device may employ a micropore system in which a laser porator creates tiny holes in the uppermost layer of a user's skin, through which interstitial glucose is measured using a patch. In the alternative, the monitoring device can use iontophoretic methods to non-invasively extract interstitial glucose for measurement. In other examples, the monitoring device can include non-invasive detection systems that employ near IR, ultrasound or spectroscopy, and particular implementations of glucose-sensing contact lenses. Invasive methods involving optical means of measuring glucose could also be added. In yet another example, the monitoring device can include an optical detection instrument that is inserted through the skin for measuring the user's glucose level. Furthermore, it should be understood that in some alternative implementations, the monitoring device 50 can be in communication with the controller device 200 or another computing device via a wired connection.
DMS 10 may optionally communicate with blood glucose meter 70 in addition to (or as an alternative to) continuous glucose monitor 50. For example, one or more test strips (e.g., blood test strips) can be inserted into a strip reader portion of blood glucose meter 70 and then receive blood to be tested. In some cases, blood glucose meter 70 is configured to analyze the characteristics of the user's blood and to communicate (e.g., via a BLUETOOTH® wireless communication connection) the information to the controller device 200. In some cases, a user can manually input a glucose meter reading. Blood glucose meter 70 can be manually operated by a user and may include an output subsystem (e.g., display, speaker) that can provide the user with blood glucose readings that can be subsequently entered into the controller or user interface (to collect the data from an unconnected BGM into the system). Blood glucose meter 70 may be configured to communicate data (e.g., blood glucose readings) obtained to the controller device 200 and/or other devices, such as the mobile computing device 60. Such communication can be over a wired and/or wireless connection, and the data can be used by the controller device 200 and/or the mobile computing device 60 to perform multiple delivery modes and/or a secondary feedback loop for the insulin delivery system 10.
DMS 10 may include one or more external medication delivery devices 80 (e.g., syringe, an insulin pen, a smart syringe with device communication capabilities, or the like) through which additional medicine dosages (e.g., insulin, glucagon) can be manually administered to a user. In some cases, user interfaces provided herein allow users to input a medication, a dosage amount, and the timing so that a closed-loop control algorithm can account for the additional medication. In some cases, mobile computing device 60 can make a recommendation for an amount of insulin to be delivered using an external delivery device.
Still referring to
In some cases, the pump assembly 15 can be configured to adhere to the user's skin directly at the location in which the skin is penetrated for medicine infusion. For example, a rear surface of the pump device 100 can include a skin adhesive patch so that the pump device 100 can be physically adhered to the skin of the user at a particular location. In these cases, the cap device 130 can have a configuration in which medicine passes directly from the cap device 130 into an infusion set 146 that is penetrated into the user's skin. In some examples, the user can temporarily detach the controller device 200 (while the pump device 100 remains adhered to the skin) so as to view and interact with the user interface.
The pump device 100 in this example includes a housing structure 110 that defines a cavity 116 in which a fluid cartridge 120 can be received. The pump device 100 also can include a cap device 130 to retain the fluid cartridge 120 in the cavity 116 of the housing structure 110. The pump device 100 can include a drive system (e.g., including a battery powered actuator, a gear system, a drive rod, and other items that are not shown) that advances a plunger 125 in the fluid cartridge 120 so as to dispense fluid therefrom. In this example, the controller device 200 communicates with the pump device 100 to control the operation of the drive system. Optionally, the controller device 200 may be configured as a reusable component that provides electronics and a user interface to control the operation of the pump device 100. In such circumstances, the pump device 100 can be a disposable component that is disposed of after a single use. For example, the pump device 100 can be a “one time use” component that is thrown away after the fluid cartridge 120 therein is exhausted. Thereafter, the user can removably attach a new pump device (having a new fluid cartridge) to the reusable controller device 200 for the dispensation of fluid from a new fluid cartridge. Accordingly, the user is permitted to reuse the controller device 200 (which may include complex or valuable electronics, as well as a rechargeable battery) while disposing of the relatively low-cost pump device 100 after each use. Such a pump assembly 15 can provide enhanced user safety as a new pump device (and drive system therein) is employed with each new fluid cartridge. Additional and/or alternative implementations of the controller device 200 are also possible, including magnetic drive turbine (MDT) monolithic architecture pumps and/or omnipods.
The pump assembly 15 can be a medical infusion pump assembly that is configured to controllably dispense a medicine from the fluid cartridge 120. As such, the fluid cartridge 120 can contain a medicine 126 to be infused into the tissue or vasculature of a targeted individual, such as a human or animal patient. For example, the pump device 100 can be adapted to receive a fluid cartridge 120 in the form of a carpule that is preloaded with insulin or another medicine for use in the treatment of Diabetes (e.g., Exenatide (BYETTA, BYDUREON) and liraglutide (VICTOZA) SYMLIN, or others). Such a fluid cartridge 120 may be supplied, for example, by Eli Lilly and Co. of Indianapolis, IN. Other examples of medicines that can be contained in the fluid cartridge 120 include: pain relief drugs, hormone therapy, blood pressure treatments, anti-emetics, osteoporosis treatments, or other injectable medicines. The fluid cartridge 120 may have other configurations. For example, the fluid cartridge 120 may comprise a reservoir that is integral with the pump housing structure 110 (e.g., the fluid cartridge 120 can be defined by one or more walls of the pump housing structure 110 that surround a plunger to define a reservoir in which the medicine is injected or otherwise received).
In some cases, the pump device 100 can include one or more structures that interfere with the removal of the fluid cartridge 120 after the fluid cartridge 120 is inserted into the cavity 116. For example, the pump housing structure 110 can include one or more retainer wings (not shown) that at least partially extend into the cavity 116 to engage a portion of the fluid cartridge 120 when the fluid cartridge 120 is installed therein. Such a configuration may facilitate the “one-time-use” feature of the pump device 100. In some cases, the retainer wings can interfere with attempts to remove the fluid cartridge 120 from the pump device 100, thus ensuring that the pump device 100 will be discarded along with the fluid cartridge 120 after the fluid cartridge 120 is emptied, expired, or otherwise exhausted. In another example, the cap device 130 can be configured to irreversibly attach to the pump housing 110 so as to cover the opening of the cavity 116. For example, a head structure of the cap device 130 can be configured to turn so as to threadably engage the cap device 130 with a mating structure along an inner wall of the cavity 116, but the head structure may prevent the cap device from turning in the reverse direction so as to disengage the threads. Accordingly, the pump device 100 can operate in a tamper-resistant and safe manner because the pump device 100 can be designed with a predetermined life expectancy (e.g., the “one-time-use” feature in which the pump device is discarded after the fluid cartridge 120 is emptied, expired, or otherwise exhausted).
Referring to
Cap device 130 of the pump device 100 can be configured to mate with an infusion set 146. In general, the infusion set 146 can be a tubing system that connects the pump assembly 15 to the tissue or vasculature of the user (e.g., to deliver medicine into the tissue or vasculature under the user's skin). The infusion set 146 can include a flexible infusion set tubing 147 that extends from the pump device 100 to a subcutaneous cannula 149 that may be retained by a skin adhesive patch (not shown) that secures the subcutaneous cannula 149 to the infusion site. The skin adhesive patch can retain the subcutaneous cannula 149 in fluid communication with the tissue or vasculature of the user so that the medicine dispensed through the infusion set tubing 147 passes through the subcutaneous cannula 149 and into the user's body. The cap device 130 can provide fluid communication between the output end 122 (
First Exemplary Occlusion Detector
Referring now to
Referring to
The fluid channel 260 arranged in the cap device 130 may include a secondary channel 262 that extends to a flexible membrane 265. In this embodiment, one side of the flexible membrane 265 is exposed to the fluid channel 260 (via the secondary channel 262) while the opposite side of the flexible membrane 265 is adjacent to an air cavity 267, which provides a volume into which the flexible membrane 265 can expand as pressure rises in the fluid channel 260. The flexible membrane 265 may comprise a flexible polymer material that bulges or otherwise deforms as the fluid pressure in the flow channel 260 rises and is preferably composed of silicon. As such, the flexible membrane 265 can flex into the air cavity 267 when the fluid pressure rises due to an occlusion in the flow path downstream of the fluid channel 260.
Referring to
The sensor circuit 252 can be arranged so that the cap device 130 is aligned with the light emitters 253, 255 and the light sensor 258 when the pump device 100 is attached to the controller device 200. It should be understood that the pump housing structure 110 and the controller housing 210 have been removed from
The sensor circuit 252 can be connected to the control circuitry 240 of the controller device 200 (
The light collector 256 can be made of any reflective material, preferably polished aluminum, and is designed to collect light from both the reference light emitter 255 and the primary light emitter 253. For example, apertures are advantageously constructed in the light collector 256 to allow light to reach the light sensor 258 from specific directions corresponding to light originating from the reference light emitter 255 and from the primary light emitter 253.
In some embodiments, the reference light emitter 255 can provide a reference light reading at the sensor 258, which can be advantageously compared to a light reading from the primary light emitter 253 for purposes of determining when a reduced light reading from the main light emitter 253 is caused by a buildup of fluid pressure in the fluid channel 260 (e.g., from an occlusion in the infusion set tubing 147) or is caused by some other reason not related to the presence of an occlusion (e.g., environmental conditions such as ambient temperature). For example, in some embodiments, the amount of light emitted from the primary light emitter 253 begins to degrade or otherwise changes with fluctuations in ambient temperature and ambient light condition. If the control circuitry was configured to rely upon the light sensor readings detected by the light sensor 258 from the primary light emitter 253 alone, such reductions in the amount of the light readings from the primary light emitter 253 would possibly induce false occlusion warnings (e.g., occlusion alerts where in fact the suboptimal temperatures are responsible for the reduced light readings and no occlusion is present in the infusion set tubing 147). In this embodiment, each of the primary light emitter 253 and the reference light emitter 255 are substantially equally affected by the fluctuations in ambient temperature and ambient light condition. Accordingly, a comparison of the amount of the light received from the primary light emitter 253 with the amount of the light received from the reference light emitter 255 (rather than an absolute light measurement from the primary light emitter 253 alone) can be employed to substantially reduce or eliminate the number of false occlusion warnings.
In other words, the amount of light emitted by the reference light emitter 255 and received by the light sensor 258 does not fluctuate according to fluid pressure but may fluctuate according to other environmental factors, such as ambient temperature (and it should be understood that primary light emitter 253 is similarly affected by these same environmental factors). This configuration can be employed to aid in the detection of an occlusion that accounts for changes in environmental factors affecting the primary light emitter 253. For example, when the infusion pump assembly 15 is operating in regions having lower ambient temperatures, both the reference light emitter 255 and the primary light emitter 253 will have reduced light outputs. In those circumstances, the occlusion detection system 250 can use the reduction in the amount of light from the reference light emitter 255 to account for the reduction in the amount of light from the primary light emitter 253. In other circumstances in which the light sensor 258 receives a reduced light signal only from the primary light emitter 253 while the light sensor 258 receive a normal light signal from the reference light emitter 255, then there is a greater likelihood of the presence of an occlusion and the user may be warned accordingly.
Referring to
For example, as shown in
Referring still to
Referring to
In a step shown by box 1604, the control circuitry 240 detects a signal corresponding to the light emitted by the reference light emitter 255 and received by the light sensor 258. For example, light transmitted from the reference light emitter 255 may reflect off of the interior surface of the light collector 256 and interact with the light sensor 258. As described in more detail above, the light sensor 258 can generate an electrical signal corresponding to the received light. Because the control circuitry 240 is in electrical communication with the light sensor 258, the control circuitry 240 detects the signal corresponding to the light emitted by the wide-angle reference light emitter 255 when the control circuitry 240 receives the electrical signal from the light sensor 258. In a preferred embodiment, each of the detected signals corresponding to light emitted by the reference light emitter 255 is a floating point value within the range of [0-1] and is stored on one more dedicated memory devices included in the control circuitry 240.
In a decision shown by step 1606, the control circuitry 240 determines whether a minimum number of light samples transmitted by the wide-angle light emitter 255 has been received. For example, in a preferred embodiment, the control circuitry 240 determines whether sixteen iterations of activating the reference light emitter 255 and detecting the corresponding sixteen electrical signals from the light sensor 258 have been completed. If the minimum number of light samples has not been received, than the control circuitry 240 may instruct the reference light emitter 255 to activate again, repeating the steps included in the first iterative step shown by box 1605. In this embodiment, the sixteen iterations can be consecutively performed in a period of 0.5 seconds or less.
Once the minimum number of light samples has been received (e.g., sixteen in this embodiment), the control circuitry 240 may perform operation 1612 to determine an average detected value of the reference light emitter samples received. For example, in a preferred embodiment, because the control circuitry 240 receives sixteen light samples from the reference light emitter 255, the sixteen light samples are added together and the total divided by sixteen to determine the average detected value of the wide-angle reference samples received. In a preferred embodiment, the determined average value corresponding to light transmitted by the reference light emitter 255 is a floating point value within the range of [0-1] and is stored on one or more dedicated memory devices included in the control circuitry 240.
In a second iterative step shown by box 1620, the control circuitry 240 activates the primary light emitter 253 as shown in a step 1614. For example, because the control circuitry 240 is in electrical communication with the primary light emitter 253, the control circuitry 240 can generate an electrical signal that when received by the primary light emitter 253 activates the primary light emitter 253 to emit light. In addition, the absence of the electrical signal may instruct the primary light emitter 253 to deactivate.
In a step 1616, the control circuitry 240 can detect a signal corresponding to the light emitted by the primary light emitter 253 and received at the light sensor 258. For example, the light transmitted from the primary light emitter 253 that passes through the light transmissive member 254, may be reflected by the interface between the light transmissive member 254 and the air cavity 267 toward the light sensor 258. As described in more detail above, the light sensor 258 can generate an electrical signal corresponding to the received light. Because the control circuitry 240 is in electrical communication with the light sensor 258, the control circuitry 240 detects the signal corresponding to the light emitted by the primary light emitter 253 when the control circuitry 240 receives the electrical signal from the light sensor 258. In a preferred embodiment, each of the detected signals corresponding to the light emitted by the primary light emitter 253 is a floating point value within the range of [0-1] and is stored on one more dedicated memory devices included in the control circuitry 240.
Still referring to
Once the minimum number of light samples has been received, in a step shown by box 1622, the control circuitry 240 determines an average detected value of the primary light emitter samples received. For example, in a preferred embodiment, because the control circuitry 240 receives 16 light samples from the primary light emitter 253, the 16 light samples are added together and the total divided by 16 to determine the average detected value of the primary light emitter samples received. In a preferred embodiment, the determined average value corresponding to light transmitted by the primary light emitter 253 is a floating point value within the range of [0-1] and is stored on one or more dedicated memory devices included in the control circuitry 240.
The process 1600 for to determining whether to sound an occlusion alarm may include an operation that compares the detected value of the light emitted by the primary light emitter 253 with the detected value of the light emitted by the reference light emitter 253. For example, in this embodiment, the step 1624 indicates that the control circuitry 240 compares the average detected value of the light emitted by the primary light emitter 253 (determined by the step shown by box 1622) with the average detected value of the light emitted by the wide-angle reference light emitter 253 (determined by the step shown by box 1612). In one example of this comparison function, the average detected value of the light emitted by the primary light emitter 253 is divided by the average detected value of the light emitted by the wide-angle reference light emitter 255. Also, in particular embodiments, the resulting comparison value is a floating point value within the range of [0-1] and is stored on one more dedicated memory devices included in the control circuitry 240.
In an optional step shown by dashed box 1626, the control circuitry 240 normalized the comparison value determined in the step shown by box 1624. For example, in a preferred embodiment, the floating point comparison value in the range of [0-1] is multiplied by 100, normalizing the comparison value to an integer value in the range of [0-100]. These percentages make up the percentages show in the right axis of
Once a percentage is determined, it can be compared to one or more threshold values to determine whether to sound an occlusion alarm in step 1628. As discussed above, thresholds can be variable for the reasons discussed above. Moreover, it in some cases, the percentages calculated in step 1626 or some other comparison coming out of step 1624 can be used to estimate a pressure and/or make other decisions illustrated in
Exemplary Medication Delivery System Having Force Sensor
Fluid infusion device 900 is designed to be carried or worn by the patient. A fluid infusion device 900 accommodates a fluid reservoir 911 for the fluid to be delivered to the user. A length of tubing 908 is the flow path that couples the fluid reservoir to the infusion set (not shown). A removable cap or fitting 910 is suitably sized and configured to accommodate replacement of fluid reservoirs (which are typically disposable) as needed. In this regard, the fitting 910 is designed to accommodate the fluid path from the fluid reservoir to the tubing 908.
Fluid infusion device includes a housing 912 and a housing end cap 914 that is coupled to an end 916 of the housing 912 to enclose components within the housing 912. These internal components include, without limitation: a battery tube subassembly 918; a sleeve 920; a slide 921; an electronics assembly 922; a drive motor assembly 924 having a drive screw 925; a force sensor 926; and a motor support cap 928. Some components that are located outside the housing 912, namely, a keypad assembly 930 and a graphic keypad overlay 932 for the keypad assembly 930. The keypad assembly 930 and the graphic keypad overlay 932 may be considered to be part of a user interface of the fluid infusion device 900. The outer edge of the motor support cap 928 is attached to the interior side of the housing 912, and the motor support cap 928 contacts the force sensor 926 to remove assembly tolerances from the drive motor assembly 924. Fluid reservoir 911 is inserted into a reservoir cavity defined within the housing 912. The reservoir cavity is configured, sized, and shaped to accommodate fluid reservoirs, and the fluid reservoir 911 is maintained in the reservoir cavity using the fitting 910. The electronics assembly 922 may include a suitably configured electronics module, which may include or cooperate with a power supply, at least one memory element, at least one processor, processing logic, and device software, firmware, and application programs.
Force sensor 926 is configured to react in response to force imparted thereto. In this regard, electrical, mechanical, magnetic, and/or other measurable or detectable characteristics of the force sensor 926 vary in accordance with the amount of force applied to the force sensor 926. Accordingly, force sensor 926 can detect forces being applied to the drive system, which is indicative of a pressure in the fluid reservoir 911.
Force sensor 926 might implement or otherwise leverage known sensor technologies, such as the sensor technology described in U.S. Pat. No. 6,485,465. As shown in
When assembled as shown in
The drive motor assembly 924 includes an electric motor 936 that is actuated and controlled by the electronics module of the fluid infusion device 900. The motor 936 can be realized as a stepper motor that rotates in a stepwise or discrete manner corresponding to the desired number of fluid delivery strokes. Alternatively, the motor 936 could be a DC motor, a solenoid, or the like. The motor 936 may optionally include an encoder (not shown), which cooperates with the electronics module of the pump device 100 to monitor the number of motor rotations or portions thereof. This in turn can be used to accurately determine the position of the slide 921, thus providing information relating to the amount of fluid dispensed from the fluid reservoir 911.
The drive motor assembly 924 can be mounted in the housing 912 using an appropriate mounting feature, structure, or element. Alternatively, the mounting could be accomplished using a shaft bearing and leaf spring or other known compliance mountings. The illustrated embodiment of the drive motor assembly 924 includes a drive member (such as the externally threaded drive gear or drive screw 925) that engages an internally threaded second drive member (such as the slide 921) having a coupler 942. The coupler 942 may be attached to or integrated with the slide 921. The slide 921 is sized to fit within the housing of the fluid reservoir 911, which enables the slide 921 to operatively cooperate with the fluid reservoir 911. The fluid reservoir 911 includes a plunger or piston 944 with at least one sealing element or feature (e.g., one or more O-rings, integral raised ridges, or a washer) for forming a fluid and air tight seal with the inner wall of the fluid reservoir 911. As mentioned previously, the fluid reservoir 911 is secured into the housing 912 with the fitting 910, which also serves as the interface between the fluid reservoir 911 and the infusion set tubing 908. For this embodiment, the piston 944 is in contact with a linear actuation member, such as the slide 921. For example, the piston 944 may have a female portion 946 that receives the coupler 942 carried by the slide 921. The female portion 946 is positioned at the end face of the piston 944, and it is sized to receive and accommodate the coupler 942. In certain embodiments, the female portion 946 includes a threaded cavity that engages external threads of the coupler 942.
Referring to
In particular embodiments, the force sensor 926 is realized as an electromechanical component having at least one variable resistance that changes as the force applied to the force sensor 926 changes. In alternative embodiments, the force sensor 926 is a capacitive sensor, a piezoresistive sensor, a piezoelectric sensor, a magnetic sensor, an optical sensor, a potentiometer, a micro-machined sensor, a linear transducer, an encoder, a strain gauge, or the like, and the detectable parameter or characteristic might be compression, shear, tension, displacement, distance, rotation, torque, force, pressure, or the like. In practice, changing characteristics of the force sensor 926 are associated with output signal characteristics that are responsive to a physical parameter to be measured. Moreover, the range and resolution of the monitored output signal provides for the desired number of output levels (e.g., different states, values, quantities, signals, magnitudes, frequencies, steps, or the like) across the range of measurement. For example, the force sensor 926 might generate a low or zero value when the applied force is relatively low, a high or maximum value when the applied force is relatively high, and intermediate values when the applied force is within the detectable range.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
This application is a divisional application of and claims priority to U.S. application Ser. No. 15/404,442, filed on Jan. 12, 2017, now U.S. Pat. No. 10,610,643, issued Apr. 7, 2020, which claims priority to U.S. Provisional Application Ser. No. 62/278,974, filed on Jan. 14, 2016.
| Number | Name | Date | Kind |
|---|---|---|---|
| 303013 | Horton | Aug 1884 | A |
| 445545 | Crane | Feb 1891 | A |
| 588583 | Lade | Aug 1897 | A |
| 1441508 | Marius et al. | Jan 1923 | A |
| 2283925 | Harvey | May 1942 | A |
| 2605765 | Kollsman | Aug 1952 | A |
| 2797149 | Skeggs | Jun 1957 | A |
| 2886529 | Guillaud | May 1959 | A |
| 3413573 | Nathanson et al. | Nov 1968 | A |
| 3574114 | Monforte | Apr 1971 | A |
| 3614554 | Shield et al. | Oct 1971 | A |
| 3631847 | Hobbs | Jan 1972 | A |
| 3634039 | Brondy | Jan 1972 | A |
| 3688764 | Reed | Sep 1972 | A |
| 3812843 | Wootten et al. | May 1974 | A |
| 3841328 | Jensen | Oct 1974 | A |
| 3885662 | Schaefer | May 1975 | A |
| 3886938 | Szabo et al. | Jun 1975 | A |
| 3963380 | Thomas et al. | Jun 1976 | A |
| 3983077 | Fuller et al. | Sep 1976 | A |
| 4055175 | Clemens et al. | Oct 1977 | A |
| 4077405 | Haerten et al. | Mar 1978 | A |
| 4108177 | Pistor | Aug 1978 | A |
| 4146029 | Ellinwood, Jr. | Mar 1979 | A |
| 4151845 | Clemens | May 1979 | A |
| 4231368 | Becker | Nov 1980 | A |
| 4235234 | Martin et al. | Nov 1980 | A |
| 4245634 | Albisser et al. | Jan 1981 | A |
| 4265241 | Portner et al. | May 1981 | A |
| 4268150 | Chen | May 1981 | A |
| 4295176 | Wittwer | Oct 1981 | A |
| 4300554 | Hessberg et al. | Nov 1981 | A |
| 4313439 | Babb et al. | Feb 1982 | A |
| 4368980 | Aldred et al. | Jan 1983 | A |
| 4373527 | Fischell | Feb 1983 | A |
| 4398908 | Siposs | Aug 1983 | A |
| 4400683 | Eda et al. | Aug 1983 | A |
| 4403984 | Ash et al. | Sep 1983 | A |
| 4424720 | Bucchianeri | Jan 1984 | A |
| 4435173 | Siposs et al. | Mar 1984 | A |
| 4443218 | DeCant et al. | Apr 1984 | A |
| 4464170 | Clemens et al. | Aug 1984 | A |
| 4469481 | Kobayashi | Sep 1984 | A |
| 4475901 | Kraegen et al. | Oct 1984 | A |
| 4493704 | Beard et al. | Jan 1985 | A |
| 4498843 | Schneider et al. | Feb 1985 | A |
| 4507115 | Kambara et al. | Mar 1985 | A |
| 4523170 | Huth, III | Jun 1985 | A |
| 4526568 | Clemens et al. | Jul 1985 | A |
| 4526569 | Bernardi | Jul 1985 | A |
| 4529401 | Leslie et al. | Jul 1985 | A |
| 4551134 | Slavik et al. | Nov 1985 | A |
| 4552561 | Eckenhoff et al. | Nov 1985 | A |
| 4559033 | Stephen et al. | Dec 1985 | A |
| 4559037 | Franetzki et al. | Dec 1985 | A |
| 4562751 | Nason et al. | Jan 1986 | A |
| 4564054 | Gustavsson | Jan 1986 | A |
| 4573968 | Parker | Mar 1986 | A |
| 4585439 | Michel | Apr 1986 | A |
| 4601707 | Albisser et al. | Jul 1986 | A |
| 4624661 | Arimond | Nov 1986 | A |
| 4633878 | Bombardieri | Jan 1987 | A |
| 4634427 | Hannula et al. | Jan 1987 | A |
| 4646038 | Wanat | Feb 1987 | A |
| 4652260 | Fenton et al. | Mar 1987 | A |
| 4657529 | Prince et al. | Apr 1987 | A |
| 4668220 | Hawrylenko | May 1987 | A |
| 4678408 | Nason et al. | Jul 1987 | A |
| 4681569 | Coble et al. | Jul 1987 | A |
| 4684368 | Kenyon | Aug 1987 | A |
| 4685903 | Cable et al. | Aug 1987 | A |
| 4731726 | Allen, III | Mar 1988 | A |
| 4734092 | Millerd | Mar 1988 | A |
| 4743243 | Vaillancourt | May 1988 | A |
| 4749109 | Kamen | Jun 1988 | A |
| 4755169 | Sarnoff et al. | Jul 1988 | A |
| 4755173 | Konopka et al. | Jul 1988 | A |
| 4759120 | Bernstein | Jul 1988 | A |
| 4768506 | Parker et al. | Sep 1988 | A |
| 4781688 | Thoma et al. | Nov 1988 | A |
| 4781693 | Martinez et al. | Nov 1988 | A |
| 4808161 | Kamen | Feb 1989 | A |
| 4838857 | Strowe et al. | Jun 1989 | A |
| 4850817 | Nason et al. | Jul 1989 | A |
| 4854170 | Brimhall et al. | Aug 1989 | A |
| 4859492 | Rogers et al. | Aug 1989 | A |
| 4880770 | Mir et al. | Nov 1989 | A |
| 4886499 | Cirelli et al. | Dec 1989 | A |
| 4898578 | Rubalcaba, Jr. | Feb 1990 | A |
| 4898579 | Groshong et al. | Feb 1990 | A |
| 4900292 | Berry et al. | Feb 1990 | A |
| 4902278 | Maget et al. | Feb 1990 | A |
| 4919596 | Slate et al. | Apr 1990 | A |
| 4925444 | Orkin et al. | May 1990 | A |
| 4940527 | Kazlauskas et al. | Jul 1990 | A |
| 4944659 | Labbe et al. | Jul 1990 | A |
| 4967201 | Rich, III | Oct 1990 | A |
| 4969874 | Michel et al. | Nov 1990 | A |
| 4975581 | Robinson et al. | Dec 1990 | A |
| 4976720 | Machold et al. | Dec 1990 | A |
| 4981140 | Wyatt | Jan 1991 | A |
| 4994047 | Walker et al. | Feb 1991 | A |
| 5007286 | Malcolm et al. | Apr 1991 | A |
| 5007458 | Marcus et al. | Apr 1991 | A |
| 5029591 | Teves | Jul 1991 | A |
| 5045064 | Driss | Sep 1991 | A |
| 5061424 | Karimi et al. | Oct 1991 | A |
| 5062841 | Siegel | Nov 1991 | A |
| 5084749 | Losee et al. | Jan 1992 | A |
| 5088981 | Howson et al. | Feb 1992 | A |
| 5088990 | Hivale et al. | Feb 1992 | A |
| 5097834 | Skrabal | Mar 1992 | A |
| 5102406 | Arnold | Apr 1992 | A |
| 5109850 | Blanco et al. | May 1992 | A |
| 5125415 | Bell | Jun 1992 | A |
| 5130675 | Sugawara | Jul 1992 | A |
| 5134079 | Cusack et al. | Jul 1992 | A |
| 5139999 | Gordon et al. | Aug 1992 | A |
| 5153827 | Coutre et al. | Oct 1992 | A |
| 5154973 | Imagawa et al. | Oct 1992 | A |
| 5165406 | Wong | Nov 1992 | A |
| 5176632 | Bernardi | Jan 1993 | A |
| 5176662 | Bartholomew et al. | Jan 1993 | A |
| 5178609 | Ishikawa | Jan 1993 | A |
| 5189609 | Tivig et al. | Feb 1993 | A |
| 5190522 | Wojcicki et al. | Mar 1993 | A |
| 5198824 | Poradish | Mar 1993 | A |
| 5205819 | Ross et al. | Apr 1993 | A |
| 5207642 | Orkin et al. | May 1993 | A |
| 5209230 | Swedlow et al. | May 1993 | A |
| 5213483 | Flaherty et al. | May 1993 | A |
| 5217754 | Santiago-Aviles et al. | Jun 1993 | A |
| 5219377 | Poradish | Jun 1993 | A |
| 5225763 | Krohn et al. | Jul 1993 | A |
| 5232439 | Campbell et al. | Aug 1993 | A |
| 5237993 | Skrabal | Aug 1993 | A |
| 5244463 | Cordner et al. | Sep 1993 | A |
| 5250027 | Lewis et al. | Oct 1993 | A |
| 5254096 | Rondelet et al. | Oct 1993 | A |
| 5257980 | Van et al. | Nov 1993 | A |
| 5261882 | Sealfon | Nov 1993 | A |
| 5263198 | Geddes et al. | Nov 1993 | A |
| 5272485 | Mason et al. | Dec 1993 | A |
| 5273517 | Barone et al. | Dec 1993 | A |
| 5281202 | Weber et al. | Jan 1994 | A |
| 5281808 | Kunkel | Jan 1994 | A |
| 5299571 | Mastrototaro | Apr 1994 | A |
| 5308982 | Ivaldi et al. | May 1994 | A |
| 5314412 | Rex | May 1994 | A |
| 5335994 | Weynant nee Girones | Aug 1994 | A |
| 5338157 | Blomquist | Aug 1994 | A |
| 5342180 | Daoud | Aug 1994 | A |
| 5342298 | Michaels et al. | Aug 1994 | A |
| 5346476 | Elson | Sep 1994 | A |
| 5349575 | Park | Sep 1994 | A |
| 5364342 | Beuchat et al. | Nov 1994 | A |
| 5377674 | Kuestner | Jan 1995 | A |
| 5380665 | Cusack et al. | Jan 1995 | A |
| 5385539 | Maynard | Jan 1995 | A |
| 5389078 | Zalesky et al. | Feb 1995 | A |
| 5395340 | Lee | Mar 1995 | A |
| 5403797 | Ohtani et al. | Apr 1995 | A |
| 5411487 | Castagna | May 1995 | A |
| 5411889 | Hoots et al. | May 1995 | A |
| 5421812 | Langley et al. | Jun 1995 | A |
| 5427988 | Sengupta et al. | Jun 1995 | A |
| 5433710 | Vanantwerp et al. | Jul 1995 | A |
| 5456945 | McMillan et al. | Oct 1995 | A |
| 5468727 | Phillips et al. | Nov 1995 | A |
| 5478610 | Desu et al. | Dec 1995 | A |
| 5505709 | Funderburk et al. | Apr 1996 | A |
| 5505828 | Wong et al. | Apr 1996 | A |
| 5507288 | Boecker et al. | Apr 1996 | A |
| 5513382 | Agahi-Kesheh et al. | Apr 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5533389 | Kamen et al. | Jul 1996 | A |
| 5535445 | Gunton | Jul 1996 | A |
| 5540772 | McMillan et al. | Jul 1996 | A |
| 5543773 | Evans et al. | Aug 1996 | A |
| 5545143 | Fischell et al. | Aug 1996 | A |
| 5551850 | Williamson et al. | Sep 1996 | A |
| 5554123 | Herskowitz | Sep 1996 | A |
| 5558640 | Pfeiler et al. | Sep 1996 | A |
| 5569186 | Lord et al. | Oct 1996 | A |
| 5582593 | Hultman | Dec 1996 | A |
| 5584053 | Kommrusch et al. | Dec 1996 | A |
| 5584813 | Livingston et al. | Dec 1996 | A |
| 5590387 | Schmidt et al. | Dec 1996 | A |
| 5609572 | Lang | Mar 1997 | A |
| 5614252 | McMillan et al. | Mar 1997 | A |
| 5625365 | Tom et al. | Apr 1997 | A |
| 5626566 | Petersen et al. | May 1997 | A |
| 5635433 | Sengupta | Jun 1997 | A |
| 5637095 | Nason et al. | Jun 1997 | A |
| 5656032 | Kriesel et al. | Aug 1997 | A |
| 5665065 | Colman et al. | Sep 1997 | A |
| 5665070 | McPhee | Sep 1997 | A |
| 5672167 | Athayde et al. | Sep 1997 | A |
| 5678539 | Schubert et al. | Oct 1997 | A |
| 5685844 | Marttila | Nov 1997 | A |
| 5685859 | Kornerup | Nov 1997 | A |
| 5693018 | Kriesel et al. | Dec 1997 | A |
| 5697899 | Hillman et al. | Dec 1997 | A |
| 5700695 | Yassinzadeh et al. | Dec 1997 | A |
| 5703364 | Rosenthal | Dec 1997 | A |
| 5707459 | Itoyama et al. | Jan 1998 | A |
| 5707715 | Derochemont et al. | Jan 1998 | A |
| 5713875 | Tanner, II | Feb 1998 | A |
| 5714123 | Sohrab | Feb 1998 | A |
| 5716343 | Kriesel et al. | Feb 1998 | A |
| 5718562 | Awless et al. | Feb 1998 | A |
| 5722397 | Eppstein | Mar 1998 | A |
| 5741216 | Hemmingsen et al. | Apr 1998 | A |
| 5741228 | Lambrecht et al. | Apr 1998 | A |
| 5746217 | Erickson et al. | May 1998 | A |
| 5747350 | Sattler | May 1998 | A |
| 5747870 | Pedder | May 1998 | A |
| 5748827 | Holl et al. | May 1998 | A |
| 5755682 | Knudson et al. | May 1998 | A |
| 5758643 | Wong et al. | Jun 1998 | A |
| 5759923 | McMillan et al. | Jun 1998 | A |
| 5764189 | Lohninger | Jun 1998 | A |
| 5766155 | Hyman et al. | Jun 1998 | A |
| 5771567 | Pierce et al. | Jun 1998 | A |
| 5772635 | Dastur et al. | Jun 1998 | A |
| 5776103 | Kriesel et al. | Jul 1998 | A |
| 5779676 | Kriesel et al. | Jul 1998 | A |
| 5785688 | Joshi et al. | Jul 1998 | A |
| 5797881 | Gadot | Aug 1998 | A |
| 5800397 | Wilson et al. | Sep 1998 | A |
| 5800405 | McPhee | Sep 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5801057 | Smart et al. | Sep 1998 | A |
| 5804048 | Wong et al. | Sep 1998 | A |
| 5807075 | Jacobsen et al. | Sep 1998 | A |
| 5816306 | Giacomel | Oct 1998 | A |
| 5817007 | Fodgaard et al. | Oct 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5822715 | Worthington et al. | Oct 1998 | A |
| 5823951 | Messerschmidt | Oct 1998 | A |
| 5839467 | Saaski et al. | Nov 1998 | A |
| 5840020 | Heinonen et al. | Nov 1998 | A |
| D403313 | Peppel | Dec 1998 | S |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851197 | Marano et al. | Dec 1998 | A |
| 5852803 | Ashby et al. | Dec 1998 | A |
| 5854608 | Leisten | Dec 1998 | A |
| 5858001 | Tsals et al. | Jan 1999 | A |
| 5858005 | Kriesel | Jan 1999 | A |
| 5858239 | Kenley et al. | Jan 1999 | A |
| 5859621 | Leisten | Jan 1999 | A |
| 5865806 | Howell | Feb 1999 | A |
| 5871470 | McWha | Feb 1999 | A |
| 5873731 | Prendergast | Feb 1999 | A |
| 5879310 | Sopp et al. | Mar 1999 | A |
| 5889459 | Hattori et al. | Mar 1999 | A |
| 5891097 | Saito et al. | Apr 1999 | A |
| 5892489 | Kanba et al. | Apr 1999 | A |
| 5893838 | Daoud et al. | Apr 1999 | A |
| 5897530 | Jackson | Apr 1999 | A |
| 5902253 | Pfeiffer et al. | May 1999 | A |
| 5903421 | Furutani et al. | May 1999 | A |
| 5906597 | McPhee | May 1999 | A |
| 5911716 | Rake et al. | Jun 1999 | A |
| 5914941 | Janky | Jun 1999 | A |
| 5919167 | Mulhauser et al. | Jul 1999 | A |
| 5925018 | Ungerstedt | Jul 1999 | A |
| 5928201 | Poulsen et al. | Jul 1999 | A |
| 5931814 | Alex et al. | Aug 1999 | A |
| 5932175 | Knute et al. | Aug 1999 | A |
| 5933121 | Rainhart et al. | Aug 1999 | A |
| 5935099 | Peterson et al. | Aug 1999 | A |
| 5945963 | Leisten | Aug 1999 | A |
| 5947911 | Wong et al. | Sep 1999 | A |
| 5947934 | Hansen et al. | Sep 1999 | A |
| 5951530 | Steengaard et al. | Sep 1999 | A |
| 5957889 | Poulsen et al. | Sep 1999 | A |
| 5957890 | Mann et al. | Sep 1999 | A |
| 5961492 | Kriesel et al. | Oct 1999 | A |
| 5965848 | Altschul et al. | Oct 1999 | A |
| 5971941 | Simons et al. | Oct 1999 | A |
| 5984894 | Poulsen et al. | Nov 1999 | A |
| 5984897 | Petersen et al. | Nov 1999 | A |
| 5993423 | Choi | Nov 1999 | A |
| 5997475 | Bortz | Dec 1999 | A |
| 5997501 | Gross et al. | Dec 1999 | A |
| 6003736 | Ljunggren | Dec 1999 | A |
| 6005151 | Herrmann et al. | Dec 1999 | A |
| 6010485 | Buch-Rasmussen et al. | Jan 2000 | A |
| 6017318 | Gauthier et al. | Jan 2000 | A |
| 6019747 | McPhee | Feb 2000 | A |
| 6023251 | Koo et al. | Feb 2000 | A |
| 6024539 | Blomquist | Feb 2000 | A |
| 6027826 | Derochemont et al. | Feb 2000 | A |
| 6028568 | Asakura et al. | Feb 2000 | A |
| 6031445 | Marty et al. | Feb 2000 | A |
| 6032059 | Henning et al. | Feb 2000 | A |
| 6033377 | Rasmussen et al. | Mar 2000 | A |
| 6036924 | Simons et al. | Mar 2000 | A |
| 6040578 | Malin et al. | Mar 2000 | A |
| 6040805 | Huynh et al. | Mar 2000 | A |
| 6045537 | Klitmose | Apr 2000 | A |
| 6046707 | Gaughan et al. | Apr 2000 | A |
| 6049727 | Crothall | Apr 2000 | A |
| 6050978 | Orr et al. | Apr 2000 | A |
| 6052040 | Hino | Apr 2000 | A |
| 6056728 | Von Schuckmann | May 2000 | A |
| 6058934 | Sullivan | May 2000 | A |
| 6066103 | Duchon et al. | May 2000 | A |
| 6071292 | Makower et al. | Jun 2000 | A |
| 6072180 | Kramer et al. | Jun 2000 | A |
| 6074372 | Hansen | Jun 2000 | A |
| 6077055 | Scott | Jun 2000 | A |
| 6090092 | Fowles et al. | Jul 2000 | A |
| 6101406 | Hacker et al. | Aug 2000 | A |
| 6102872 | Doneen et al. | Aug 2000 | A |
| 6106498 | Friedli et al. | Aug 2000 | A |
| 6110149 | Klitgaard et al. | Aug 2000 | A |
| 6111544 | Dakeya et al. | Aug 2000 | A |
| 6115673 | Malin et al. | Sep 2000 | A |
| 6123827 | Wong et al. | Sep 2000 | A |
| 6124134 | Stark | Sep 2000 | A |
| 6126595 | Amano et al. | Oct 2000 | A |
| 6126637 | Kriesel et al. | Oct 2000 | A |
| 6127061 | Shun et al. | Oct 2000 | A |
| 6128519 | Say | Oct 2000 | A |
| 6142939 | Eppstein et al. | Nov 2000 | A |
| 6143164 | Heller et al. | Nov 2000 | A |
| 6143432 | De et al. | Nov 2000 | A |
| 6154176 | Fathy et al. | Nov 2000 | A |
| 6156014 | Petersen et al. | Dec 2000 | A |
| 6157041 | Thomas et al. | Dec 2000 | A |
| 6161028 | Braig et al. | Dec 2000 | A |
| 6162639 | Douglas | Dec 2000 | A |
| 6171276 | Lippe et al. | Jan 2001 | B1 |
| 6174300 | Kriesel et al. | Jan 2001 | B1 |
| 6176004 | Rainhart et al. | Jan 2001 | B1 |
| 6181297 | Leisten | Jan 2001 | B1 |
| 6188368 | Koriyama et al. | Feb 2001 | B1 |
| 6190359 | Heruth | Feb 2001 | B1 |
| 6195049 | Kim et al. | Feb 2001 | B1 |
| 6196046 | Braig et al. | Mar 2001 | B1 |
| 6200287 | Keller et al. | Mar 2001 | B1 |
| 6200293 | Kriesel et al. | Mar 2001 | B1 |
| 6200338 | Solomon et al. | Mar 2001 | B1 |
| 6204203 | Narwankar et al. | Mar 2001 | B1 |
| 6208843 | Huang et al. | Mar 2001 | B1 |
| 6214629 | Freitag et al. | Apr 2001 | B1 |
| 6222489 | Tsuru et al. | Apr 2001 | B1 |
| 6226082 | Roe | May 2001 | B1 |
| 6231540 | Smedegaard | May 2001 | B1 |
| 6233471 | Berner et al. | May 2001 | B1 |
| 6244776 | Wiley | Jun 2001 | B1 |
| 6248067 | Causey et al. | Jun 2001 | B1 |
| 6248090 | Jensen et al. | Jun 2001 | B1 |
| 6248093 | Moberg | Jun 2001 | B1 |
| 6251113 | Appelbaum et al. | Jun 2001 | B1 |
| 6261065 | Nayak et al. | Jul 2001 | B1 |
| 6262798 | Shepherd et al. | Jul 2001 | B1 |
| 6266020 | Chang | Jul 2001 | B1 |
| 6269340 | Ford et al. | Jul 2001 | B1 |
| 6270455 | Brown | Aug 2001 | B1 |
| 6271045 | Douglas et al. | Aug 2001 | B1 |
| 6277098 | Klitmose et al. | Aug 2001 | B1 |
| 6280381 | Malin et al. | Aug 2001 | B1 |
| 6285448 | Kuenstner | Sep 2001 | B1 |
| 6292440 | Lee | Sep 2001 | B1 |
| 6300894 | Lynch et al. | Oct 2001 | B1 |
| 6302855 | Lav et al. | Oct 2001 | B1 |
| 6302869 | Klitgaard | Oct 2001 | B1 |
| 6309370 | Haim et al. | Oct 2001 | B1 |
| 6312888 | Wong et al. | Nov 2001 | B1 |
| 6320547 | Fathy et al. | Nov 2001 | B1 |
| 6323549 | Derochemont et al. | Nov 2001 | B1 |
| 6334851 | Hayes et al. | Jan 2002 | B1 |
| 6363609 | Pickren | Apr 2002 | B1 |
| 6368314 | Kipfer et al. | Apr 2002 | B1 |
| 6375627 | Mauze et al. | Apr 2002 | B1 |
| 6375638 | Nason et al. | Apr 2002 | B2 |
| 6379301 | Worthington et al. | Apr 2002 | B1 |
| 6379339 | Klitgaard et al. | Apr 2002 | B1 |
| 6381496 | Meadows et al. | Apr 2002 | B1 |
| 6397098 | Uber et al. | May 2002 | B1 |
| 6402689 | Scarantino et al. | Jun 2002 | B1 |
| 6404098 | Kayama et al. | Jun 2002 | B1 |
| 6413244 | Bestetti et al. | Jul 2002 | B1 |
| 6427088 | Bowman et al. | Jul 2002 | B1 |
| D461241 | Moberg et al. | Aug 2002 | S |
| D461891 | Moberg | Aug 2002 | S |
| 6434528 | Sanders | Aug 2002 | B1 |
| 6436072 | Kullas et al. | Aug 2002 | B1 |
| 6461329 | Van et al. | Oct 2002 | B1 |
| 6461331 | Van Antwerp | Oct 2002 | B1 |
| 6470279 | Samsoondar | Oct 2002 | B1 |
| 6474219 | Klitmose et al. | Nov 2002 | B2 |
| 6475196 | Vachon | Nov 2002 | B1 |
| 6477065 | Parks | Nov 2002 | B2 |
| 6477901 | Tadigadapa et al. | Nov 2002 | B1 |
| 6484044 | Lilienfeld-Toal | Nov 2002 | B1 |
| 6485461 | Mason et al. | Nov 2002 | B1 |
| 6485462 | Kriesel | Nov 2002 | B1 |
| 6491656 | Morris | Dec 2002 | B1 |
| 6491684 | Joshi et al. | Dec 2002 | B1 |
| 6492949 | Breglia et al. | Dec 2002 | B1 |
| 6496149 | Birnbaum et al. | Dec 2002 | B1 |
| 6501415 | Viana et al. | Dec 2002 | B1 |
| 6508788 | Preuthun | Jan 2003 | B2 |
| 6512937 | Blank et al. | Jan 2003 | B2 |
| 6520936 | Mann | Feb 2003 | B1 |
| 6524280 | Hansen et al. | Feb 2003 | B2 |
| 6525509 | Petersson et al. | Feb 2003 | B1 |
| 6527744 | Kriesel et al. | Mar 2003 | B1 |
| 6528809 | Thomas et al. | Mar 2003 | B1 |
| 6533183 | Aasmul et al. | Mar 2003 | B2 |
| 6537249 | Kriesell et al. | Mar 2003 | B2 |
| 6537251 | Klitmose | Mar 2003 | B2 |
| 6537268 | Gibson et al. | Mar 2003 | B1 |
| 6540260 | Tan | Apr 2003 | B1 |
| 6540672 | Simonsen et al. | Apr 2003 | B1 |
| 6541820 | Bol | Apr 2003 | B1 |
| 6544212 | Galley et al. | Apr 2003 | B2 |
| 6544229 | Danby et al. | Apr 2003 | B1 |
| 6546268 | Ishikawa et al. | Apr 2003 | B1 |
| 6546269 | Kurnik | Apr 2003 | B1 |
| 6547764 | Larsen et al. | Apr 2003 | B2 |
| 6551276 | Mann et al. | Apr 2003 | B1 |
| 6552693 | Leisten | Apr 2003 | B1 |
| 6553841 | Blouch | Apr 2003 | B1 |
| 6554798 | Mann et al. | Apr 2003 | B1 |
| 6554800 | Nezhadian et al. | Apr 2003 | B1 |
| 6556850 | Braig et al. | Apr 2003 | B1 |
| D474778 | Barnes | May 2003 | S |
| 6558320 | Causey et al. | May 2003 | B1 |
| 6558345 | Houben et al. | May 2003 | B1 |
| 6558351 | Steil et al. | May 2003 | B1 |
| 6559735 | Hoang et al. | May 2003 | B1 |
| 6560471 | Heller et al. | May 2003 | B1 |
| 6561978 | Conn et al. | May 2003 | B1 |
| 6562001 | Lebel et al. | May 2003 | B2 |
| 6562011 | Buch-Rasmussen et al. | May 2003 | B1 |
| 6562014 | Lin et al. | May 2003 | B2 |
| 6564105 | Starkweather et al. | May 2003 | B2 |
| 6569115 | Barker et al. | May 2003 | B1 |
| 6569125 | Jepson et al. | May 2003 | B2 |
| 6569126 | Poulsen et al. | May 2003 | B1 |
| 6571128 | Lebel et al. | May 2003 | B2 |
| 6572542 | Houben et al. | Jun 2003 | B1 |
| 6572545 | Knobbe et al. | Jun 2003 | B2 |
| 6574490 | Abbink et al. | Jun 2003 | B2 |
| 6575905 | Knobbe et al. | Jun 2003 | B2 |
| 6577899 | Lebel et al. | Jun 2003 | B2 |
| 6580934 | Braig et al. | Jun 2003 | B1 |
| 6582404 | Klitgaard et al. | Jun 2003 | B1 |
| 6583699 | Yokoyama | Jun 2003 | B2 |
| 6585644 | Lebel et al. | Jul 2003 | B2 |
| 6585699 | Ljunggreen et al. | Jul 2003 | B2 |
| 6587199 | Luu | Jul 2003 | B1 |
| 6589229 | Connelly et al. | Jul 2003 | B1 |
| 6595956 | Gross et al. | Jul 2003 | B1 |
| 6599281 | Struys et al. | Jul 2003 | B1 |
| 6605067 | Larsen | Aug 2003 | B1 |
| 6605072 | Struys et al. | Aug 2003 | B2 |
| 6611419 | Chakravorty | Aug 2003 | B1 |
| 6613019 | Munk | Sep 2003 | B2 |
| 6618603 | Varalli et al. | Sep 2003 | B2 |
| 6620750 | Kim et al. | Sep 2003 | B2 |
| 6633772 | Ford et al. | Oct 2003 | B2 |
| 6635958 | Bates et al. | Oct 2003 | B2 |
| 6639556 | Baba | Oct 2003 | B2 |
| 6641533 | Causey et al. | Nov 2003 | B2 |
| 6642908 | Pleva et al. | Nov 2003 | B2 |
| 6645142 | Braig et al. | Nov 2003 | B2 |
| 6648821 | Lebel et al. | Nov 2003 | B2 |
| 6650303 | Kim et al. | Nov 2003 | B2 |
| 6650951 | Jones et al. | Nov 2003 | B1 |
| 6653091 | Dunn et al. | Nov 2003 | B1 |
| 6656158 | Mahoney et al. | Dec 2003 | B2 |
| 6656159 | Flaherty | Dec 2003 | B2 |
| 6659948 | Lebel et al. | Dec 2003 | B2 |
| 6659978 | Kasuga et al. | Dec 2003 | B1 |
| 6659980 | Moberg et al. | Dec 2003 | B2 |
| 6662030 | Khalil et al. | Dec 2003 | B2 |
| 6663602 | Moeller | Dec 2003 | B2 |
| 6668196 | Villegas et al. | Dec 2003 | B1 |
| 6669663 | Thompson | Dec 2003 | B1 |
| 6669668 | Kleeman et al. | Dec 2003 | B1 |
| 6669669 | Flaherty et al. | Dec 2003 | B2 |
| 6670497 | Tashino et al. | Dec 2003 | B2 |
| 6678542 | Braig et al. | Jan 2004 | B2 |
| 6680700 | Hilgers | Jan 2004 | B2 |
| 6683576 | Achim | Jan 2004 | B2 |
| 6685674 | Douglas et al. | Feb 2004 | B2 |
| 6686406 | Tomomatsu et al. | Feb 2004 | B2 |
| 6687546 | Lebel et al. | Feb 2004 | B2 |
| 6689100 | Connelly et al. | Feb 2004 | B2 |
| 6690192 | Wing | Feb 2004 | B1 |
| 6690336 | Leisten et al. | Feb 2004 | B1 |
| 6691043 | Ribeiro, Jr. | Feb 2004 | B2 |
| 6692457 | Flaherty | Feb 2004 | B2 |
| 6692472 | Hansen et al. | Feb 2004 | B2 |
| 6694191 | Starkweather et al. | Feb 2004 | B2 |
| 6697605 | Atokawa et al. | Feb 2004 | B1 |
| 6699218 | Flaherty et al. | Mar 2004 | B2 |
| 6699221 | Vaillancourt | Mar 2004 | B2 |
| 6702779 | Connelly et al. | Mar 2004 | B2 |
| 6715516 | Ohms et al. | Apr 2004 | B2 |
| 6716198 | Larsen | Apr 2004 | B2 |
| 6718189 | Rohrscheib et al. | Apr 2004 | B2 |
| 6720926 | Killen et al. | Apr 2004 | B2 |
| 6721582 | Trepagnier et al. | Apr 2004 | B2 |
| 6723072 | Flaherty et al. | Apr 2004 | B2 |
| 6723077 | Pickup et al. | Apr 2004 | B2 |
| 6727785 | Killen et al. | Apr 2004 | B2 |
| 6728560 | Kollias et al. | Apr 2004 | B2 |
| 6731244 | Killen et al. | May 2004 | B2 |
| 6731248 | Killen et al. | May 2004 | B2 |
| 6733446 | Lebel et al. | May 2004 | B2 |
| 6733890 | Imanaka et al. | May 2004 | B2 |
| 6736796 | Shekalim | May 2004 | B2 |
| 6740059 | Flaherty | May 2004 | B2 |
| 6740072 | Starkweather et al. | May 2004 | B2 |
| 6740075 | Lebel et al. | May 2004 | B2 |
| 6741148 | Killen et al. | May 2004 | B2 |
| 6742249 | DeRochemont et al. | Jun 2004 | B2 |
| 6743744 | Kim et al. | Jun 2004 | B1 |
| 6744350 | Blomquist | Jun 2004 | B2 |
| 6749587 | Flaherty | Jun 2004 | B2 |
| 6750740 | Killen et al. | Jun 2004 | B2 |
| 6750820 | Killen et al. | Jun 2004 | B2 |
| 6751490 | Esenaliev et al. | Jun 2004 | B2 |
| 6752785 | Van et al. | Jun 2004 | B2 |
| 6752787 | Causey et al. | Jun 2004 | B1 |
| 6753745 | Killen et al. | Jun 2004 | B2 |
| 6753814 | Killen et al. | Jun 2004 | B2 |
| 6758810 | Lebel et al. | Jul 2004 | B2 |
| 6758835 | Close et al. | Jul 2004 | B2 |
| 6761286 | Py et al. | Jul 2004 | B2 |
| 6762237 | Glatkowski et al. | Jul 2004 | B2 |
| 6768425 | Flaherty et al. | Jul 2004 | B2 |
| 6780156 | Haueter et al. | Aug 2004 | B2 |
| 6786246 | Ohms et al. | Sep 2004 | B2 |
| 6786890 | Preuthun et al. | Sep 2004 | B2 |
| 6787181 | Uchiyama et al. | Sep 2004 | B2 |
| 6791496 | Killen et al. | Sep 2004 | B1 |
| 6796957 | Carpenter et al. | Sep 2004 | B2 |
| 6796970 | Klitmose et al. | Sep 2004 | B1 |
| 6799149 | Hartlaub | Sep 2004 | B2 |
| 6809653 | Mann et al. | Oct 2004 | B1 |
| 6810290 | Lebel et al. | Oct 2004 | B2 |
| 6811533 | Lebel et al. | Nov 2004 | B2 |
| 6811534 | Bowman et al. | Nov 2004 | B2 |
| 6813519 | Ebel et al. | Nov 2004 | B2 |
| 6826031 | Nagai et al. | Nov 2004 | B2 |
| 6827702 | Lebel et al. | Dec 2004 | B2 |
| 6830558 | Flaherty et al. | Dec 2004 | B2 |
| 6830623 | Hayashi et al. | Dec 2004 | B2 |
| 6837858 | Cunningham et al. | Jan 2005 | B2 |
| 6837988 | Leong et al. | Jan 2005 | B2 |
| 6846288 | Nagar et al. | Jan 2005 | B2 |
| 6852104 | Blomquist | Feb 2005 | B2 |
| 6853288 | Ahn et al. | Feb 2005 | B2 |
| 6854620 | Ramey | Feb 2005 | B2 |
| 6854653 | Eilersen | Feb 2005 | B2 |
| 6855129 | Jensen et al. | Feb 2005 | B2 |
| 6858892 | Yamagata | Feb 2005 | B2 |
| 6862534 | Sterling et al. | Mar 2005 | B2 |
| 6864848 | Sievenpiper | Mar 2005 | B2 |
| 6865408 | Abbink et al. | Mar 2005 | B1 |
| 6871396 | Sugaya et al. | Mar 2005 | B2 |
| 6872200 | Mann et al. | Mar 2005 | B2 |
| 6873268 | Lebel et al. | Mar 2005 | B2 |
| 6878132 | Kipfer | Apr 2005 | B2 |
| 6878871 | Scher et al. | Apr 2005 | B2 |
| 6883778 | Newton et al. | Apr 2005 | B1 |
| 6890291 | Robinson et al. | May 2005 | B2 |
| 6893415 | Madsen et al. | May 2005 | B2 |
| 6899695 | Herrera | May 2005 | B2 |
| 6899699 | Enggaard | May 2005 | B2 |
| 6905989 | Ellis et al. | Jun 2005 | B2 |
| 6906674 | McKinzie et al. | Jun 2005 | B2 |
| 6914566 | Beard | Jul 2005 | B2 |
| 6919119 | Kalkan et al. | Jul 2005 | B2 |
| 6922590 | Whitehurst | Jul 2005 | B1 |
| 6923763 | Kovatchev et al. | Aug 2005 | B1 |
| 6925393 | Kalatz et al. | Aug 2005 | B1 |
| 6928298 | Furutani et al. | Aug 2005 | B2 |
| 6936006 | Sabra | Aug 2005 | B2 |
| 6936029 | Mann et al. | Aug 2005 | B2 |
| 6943430 | Kwon | Sep 2005 | B2 |
| 6943731 | Killen et al. | Sep 2005 | B2 |
| 6945961 | Miller et al. | Sep 2005 | B2 |
| 6949081 | Chance | Sep 2005 | B1 |
| 6950708 | Bowman et al. | Sep 2005 | B2 |
| 6958809 | Sterling et al. | Oct 2005 | B2 |
| 6960192 | Flaherty et al. | Nov 2005 | B1 |
| 6963259 | Killen et al. | Nov 2005 | B2 |
| 6979326 | Mann et al. | Dec 2005 | B2 |
| 6989891 | Braig et al. | Jan 2006 | B2 |
| 6990366 | Say et al. | Jan 2006 | B2 |
| 6997911 | Klitmose | Feb 2006 | B2 |
| 6997920 | Mann et al. | Feb 2006 | B2 |
| 7002436 | Ma et al. | Feb 2006 | B2 |
| 7005078 | Van et al. | Feb 2006 | B2 |
| 7008399 | Larsen et al. | Mar 2006 | B2 |
| 7008404 | Nakajima | Mar 2006 | B2 |
| 7009180 | Sterling et al. | Mar 2006 | B2 |
| 7014625 | Bengtsson | Mar 2006 | B2 |
| 7016713 | Gardner et al. | Mar 2006 | B2 |
| 7018360 | Flaherty et al. | Mar 2006 | B2 |
| 7025743 | Mann et al. | Apr 2006 | B2 |
| 7025744 | Utterberg et al. | Apr 2006 | B2 |
| 7027848 | Robinson et al. | Apr 2006 | B2 |
| 7029455 | Flaherty | Apr 2006 | B2 |
| 7043288 | Davis et al. | May 2006 | B2 |
| 7047637 | Derochemont et al. | May 2006 | B2 |
| 7054836 | Christensen et al. | May 2006 | B2 |
| 7060059 | Keith et al. | Jun 2006 | B2 |
| 7060350 | Takaya et al. | Jun 2006 | B2 |
| 7061593 | Braig et al. | Jun 2006 | B2 |
| 7066910 | Bauhahn et al. | Jun 2006 | B2 |
| 7070580 | Nielsen | Jul 2006 | B2 |
| 7096124 | Sterling et al. | Aug 2006 | B2 |
| 7098803 | Mann et al. | Aug 2006 | B2 |
| 7104972 | Moller et al. | Sep 2006 | B2 |
| 7109878 | Mann et al. | Sep 2006 | B2 |
| 7115205 | Robinson et al. | Oct 2006 | B2 |
| 7116949 | Irie et al. | Oct 2006 | B2 |
| 7123964 | Betzold et al. | Oct 2006 | B2 |
| 7133329 | Skyggebjerg et al. | Nov 2006 | B2 |
| 7137694 | Ferran et al. | Nov 2006 | B2 |
| 7139593 | Kavak et al. | Nov 2006 | B2 |
| 7139598 | Hull et al. | Nov 2006 | B2 |
| 7144384 | Gorman et al. | Dec 2006 | B2 |
| 7160272 | Eyal et al. | Jan 2007 | B1 |
| 7171252 | Scarantino et al. | Jan 2007 | B1 |
| 7172572 | Diamond et al. | Feb 2007 | B2 |
| 7179226 | Crothall et al. | Feb 2007 | B2 |
| 7190988 | Say et al. | Mar 2007 | B2 |
| 7204823 | Estes et al. | Apr 2007 | B2 |
| 7220240 | Struys et al. | May 2007 | B2 |
| 7230316 | Yamazaki et al. | Jun 2007 | B2 |
| 7232423 | Mernoee | Jun 2007 | B2 |
| 7248912 | Gough et al. | Jul 2007 | B2 |
| 7267665 | Steil et al. | Sep 2007 | B2 |
| 7271912 | Sterling et al. | Sep 2007 | B2 |
| 7278983 | Ireland et al. | Oct 2007 | B2 |
| 7291107 | Hellwig et al. | Nov 2007 | B2 |
| 7291497 | Holmes et al. | Nov 2007 | B2 |
| 7291782 | Sager et al. | Nov 2007 | B2 |
| 7303549 | Flaherty et al. | Dec 2007 | B2 |
| 7303622 | Loch et al. | Dec 2007 | B2 |
| 7303922 | Jeng et al. | Dec 2007 | B2 |
| 7354420 | Steil et al. | Apr 2008 | B2 |
| 7388202 | Sterling et al. | Jun 2008 | B2 |
| 7402153 | Steil et al. | Jul 2008 | B2 |
| 7404796 | Ginsberg | Jul 2008 | B2 |
| 7405698 | De Rochemont | Jul 2008 | B2 |
| 7429255 | Thompson | Sep 2008 | B2 |
| 7460130 | Salganicoff | Dec 2008 | B2 |
| 7481787 | Gable et al. | Jan 2009 | B2 |
| 7491187 | Van et al. | Feb 2009 | B2 |
| 7494481 | Moberg et al. | Feb 2009 | B2 |
| 7500949 | Gottlieb et al. | Mar 2009 | B2 |
| 7509156 | Flanders | Mar 2009 | B2 |
| D590415 | Ball et al. | Apr 2009 | S |
| 7522124 | Smith et al. | Apr 2009 | B2 |
| 7547281 | Hayes et al. | Jun 2009 | B2 |
| 7553281 | Hellwig et al. | Jun 2009 | B2 |
| 7553512 | Kodas et al. | Jun 2009 | B2 |
| 7564887 | Wang et al. | Jul 2009 | B2 |
| 7569030 | Lebel et al. | Aug 2009 | B2 |
| 7569050 | Moberg et al. | Aug 2009 | B2 |
| 7570980 | Ginsberg | Aug 2009 | B2 |
| 7591801 | Brauker et al. | Sep 2009 | B2 |
| 7595623 | Bennett | Sep 2009 | B2 |
| 7597682 | Moberg | Oct 2009 | B2 |
| 7608042 | Goldberger et al. | Oct 2009 | B2 |
| 7641649 | Moberg et al. | Jan 2010 | B2 |
| 7651845 | Doyle et al. | Jan 2010 | B2 |
| 7652901 | Kirchmeier et al. | Jan 2010 | B2 |
| 7654982 | Carlisle et al. | Feb 2010 | B2 |
| 7670288 | Sher | Mar 2010 | B2 |
| 7680529 | Kroll | Mar 2010 | B2 |
| D614634 | Nilsen | Apr 2010 | S |
| 7708717 | Estes et al. | May 2010 | B2 |
| 7714794 | Tavassoli Hozouri | May 2010 | B2 |
| 7734323 | Blomquist et al. | Jun 2010 | B2 |
| 7763917 | De Rochemont | Jul 2010 | B2 |
| 7766829 | Sloan et al. | Aug 2010 | B2 |
| 7771391 | Carter | Aug 2010 | B2 |
| 7785258 | Braig et al. | Aug 2010 | B2 |
| 7785313 | Mastrototaro | Aug 2010 | B2 |
| 7789859 | Estes et al. | Sep 2010 | B2 |
| 7794426 | Briones et al. | Sep 2010 | B2 |
| 7806853 | Wittmann et al. | Oct 2010 | B2 |
| 7806854 | Damiano et al. | Oct 2010 | B2 |
| 7812774 | Friman et al. | Oct 2010 | B2 |
| 7815602 | Mann et al. | Oct 2010 | B2 |
| 7819843 | Mann et al. | Oct 2010 | B2 |
| 7828528 | Estes et al. | Nov 2010 | B2 |
| 7850641 | Lebel et al. | Dec 2010 | B2 |
| 7904061 | Zaffino et al. | Mar 2011 | B1 |
| 7918825 | O'Connor et al. | Apr 2011 | B2 |
| 7938797 | Estes | May 2011 | B2 |
| 7938801 | Hawkins et al. | May 2011 | B2 |
| 7946985 | Mastrototaro et al. | May 2011 | B2 |
| D640269 | Chen | Jun 2011 | S |
| 7959598 | Estes | Jun 2011 | B2 |
| 7967812 | Jasperson et al. | Jun 2011 | B2 |
| 7972296 | Braig et al. | Jul 2011 | B2 |
| 7976492 | Brauker et al. | Jul 2011 | B2 |
| 8029459 | Rush et al. | Oct 2011 | B2 |
| 8057436 | Causey et al. | Nov 2011 | B2 |
| 8062249 | Wilinska et al. | Nov 2011 | B2 |
| 8065096 | Moberg | Nov 2011 | B2 |
| 8066805 | Zuercher et al. | Nov 2011 | B2 |
| 8069690 | DeSantolo et al. | Dec 2011 | B2 |
| 8105268 | Lebel et al. | Jan 2012 | B2 |
| 8114023 | Ward et al. | Feb 2012 | B2 |
| 8114489 | Nemat-Nasser et al. | Feb 2012 | B2 |
| 8152789 | Starkweather et al. | Apr 2012 | B2 |
| 8178457 | De Rochemont | May 2012 | B2 |
| 8182461 | Pope | May 2012 | B2 |
| 8193873 | Kato et al. | Jun 2012 | B2 |
| 8206296 | Jennewine | Jun 2012 | B2 |
| 8206350 | Mann et al. | Jun 2012 | B2 |
| 8208984 | Blomquist et al. | Jun 2012 | B2 |
| 8221345 | Blomquist | Jul 2012 | B2 |
| 8221385 | Estes | Jul 2012 | B2 |
| 8226556 | Hayes et al. | Jul 2012 | B2 |
| 8246540 | Ginsberg | Aug 2012 | B2 |
| 8251907 | Sterling et al. | Aug 2012 | B2 |
| 8262616 | Grant et al. | Sep 2012 | B2 |
| 8267893 | Moberg et al. | Sep 2012 | B2 |
| 8267921 | Yodfat et al. | Sep 2012 | B2 |
| 8273052 | Damiano et al. | Sep 2012 | B2 |
| D669165 | Sims et al. | Oct 2012 | S |
| 8282626 | Wenger et al. | Oct 2012 | B2 |
| 8287487 | Estes | Oct 2012 | B2 |
| 8318154 | Frost et al. | Nov 2012 | B2 |
| 8348844 | Kunjan et al. | Jan 2013 | B2 |
| 8348886 | Kanderian et al. | Jan 2013 | B2 |
| 8348923 | Kanderian et al. | Jan 2013 | B2 |
| 8350657 | Derochemont | Jan 2013 | B2 |
| 8352011 | Van et al. | Jan 2013 | B2 |
| 8354294 | De et al. | Jan 2013 | B2 |
| 8372039 | Mernoe et al. | Feb 2013 | B2 |
| D677685 | Simmons et al. | Mar 2013 | S |
| 8409142 | Causey et al. | Apr 2013 | B2 |
| 8417311 | Rule | Apr 2013 | B2 |
| 8430847 | Mernoe et al. | Apr 2013 | B2 |
| 8439834 | Schmelzeisen-Redeker et al. | May 2013 | B2 |
| 8439897 | Yodfat et al. | May 2013 | B2 |
| 8449524 | Braig et al. | May 2013 | B2 |
| 8452359 | Rebec et al. | May 2013 | B2 |
| 8454510 | Yodfat et al. | Jun 2013 | B2 |
| 8454576 | Mastrototaro et al. | Jun 2013 | B2 |
| 8460231 | Brauker et al. | Jun 2013 | B2 |
| 8467972 | Rush | Jun 2013 | B2 |
| 8467980 | Campbell et al. | Jun 2013 | B2 |
| 8475409 | Tsoukalis | Jul 2013 | B2 |
| 8478557 | Hayter et al. | Jul 2013 | B2 |
| 8480655 | Jasperson et al. | Jul 2013 | B2 |
| D688686 | Rhee et al. | Aug 2013 | S |
| 8547239 | Peatfield et al. | Oct 2013 | B2 |
| 8548544 | Kircher et al. | Oct 2013 | B2 |
| 8548552 | Tsoukalis | Oct 2013 | B2 |
| 8551045 | Sie et al. | Oct 2013 | B2 |
| 8560082 | Wei | Oct 2013 | B2 |
| 8560131 | Haueter et al. | Oct 2013 | B2 |
| 8562558 | Kamath et al. | Oct 2013 | B2 |
| 8562587 | Kovatchev et al. | Oct 2013 | B2 |
| 8568713 | Frost et al. | Oct 2013 | B2 |
| D693837 | Bouchier | Nov 2013 | S |
| 8579854 | Budiman et al. | Nov 2013 | B2 |
| 8579879 | Palerm et al. | Nov 2013 | B2 |
| 8585591 | Sloan et al. | Nov 2013 | B2 |
| 8585593 | Kovatchev et al. | Nov 2013 | B2 |
| 8585637 | Wilinska et al. | Nov 2013 | B2 |
| 8585638 | Blomquist | Nov 2013 | B2 |
| 8593819 | De Rochemont | Nov 2013 | B2 |
| D695757 | Ray et al. | Dec 2013 | S |
| 8597274 | Sloan et al. | Dec 2013 | B2 |
| 8615366 | Galley et al. | Dec 2013 | B2 |
| 8622988 | Hayter | Jan 2014 | B2 |
| 8679016 | Mastrototaro et al. | Mar 2014 | B2 |
| 8679060 | Mernoe et al. | Mar 2014 | B2 |
| 8690820 | Cinar et al. | Apr 2014 | B2 |
| 8694115 | Goetz et al. | Apr 2014 | B2 |
| 8706691 | McDaniel et al. | Apr 2014 | B2 |
| 8715839 | De Rochemont | May 2014 | B2 |
| 8718949 | Blomquist et al. | May 2014 | B2 |
| 8721585 | Brauker et al. | May 2014 | B2 |
| 8727982 | Jennewine | May 2014 | B2 |
| 8734422 | Hayter | May 2014 | B2 |
| 8734428 | Blomquist | May 2014 | B2 |
| 8747315 | Brauker et al. | Jun 2014 | B2 |
| 8762070 | Doyle et al. | Jun 2014 | B2 |
| 8771222 | Kanderian et al. | Jul 2014 | B2 |
| 8777896 | Starkweather et al. | Jul 2014 | B2 |
| 8777924 | Kanderian et al. | Jul 2014 | B2 |
| 8784364 | Kamen et al. | Jul 2014 | B2 |
| 8784369 | Starkweather et al. | Jul 2014 | B2 |
| 8784370 | Lebel et al. | Jul 2014 | B2 |
| 8790294 | Estes | Jul 2014 | B2 |
| D710879 | Elston et al. | Aug 2014 | S |
| 8795224 | Starkweather et al. | Aug 2014 | B2 |
| 8795252 | Hayter | Aug 2014 | B2 |
| 8808230 | Rotstein | Aug 2014 | B2 |
| 8810394 | Kalpin | Aug 2014 | B2 |
| D714822 | Capua et al. | Oct 2014 | S |
| D715315 | Wood | Oct 2014 | S |
| D715815 | Bortman et al. | Oct 2014 | S |
| 8852141 | Mhatre et al. | Oct 2014 | B2 |
| 8876755 | Taub et al. | Nov 2014 | B2 |
| 8882741 | Brauker et al. | Nov 2014 | B2 |
| D718779 | Hang et al. | Dec 2014 | S |
| D720366 | Hiltunen et al. | Dec 2014 | S |
| 8903501 | Perryman | Dec 2014 | B2 |
| 8919180 | Gottlieb et al. | Dec 2014 | B2 |
| 8920401 | Brauker et al. | Dec 2014 | B2 |
| D720765 | Xie et al. | Jan 2015 | S |
| 8926585 | Brauker et al. | Jan 2015 | B2 |
| 8939935 | O'Connor et al. | Jan 2015 | B2 |
| 8945094 | Nordh | Feb 2015 | B2 |
| 8956291 | Valk et al. | Feb 2015 | B2 |
| 8956321 | DeJournett | Feb 2015 | B2 |
| 8977504 | Hovorka | Mar 2015 | B2 |
| 8992475 | Mann et al. | Mar 2015 | B2 |
| D726760 | Yokota et al. | Apr 2015 | S |
| D727928 | Allison et al. | Apr 2015 | S |
| D730378 | Xiong et al. | May 2015 | S |
| 9034323 | Frost et al. | May 2015 | B2 |
| D733175 | Bae | Jun 2015 | S |
| 9050413 | Brauker et al. | Jun 2015 | B2 |
| 9056165 | Steil et al. | Jun 2015 | B2 |
| 9056168 | Kircher et al. | Jun 2015 | B2 |
| 9061097 | Holt et al. | Jun 2015 | B2 |
| D734356 | Xiong et al. | Jul 2015 | S |
| 9078963 | Estes | Jul 2015 | B2 |
| 9089305 | Hovorka | Jul 2015 | B2 |
| D736811 | Teichner et al. | Aug 2015 | S |
| D737305 | Scazafavo et al. | Aug 2015 | S |
| D737831 | Lee | Sep 2015 | S |
| D737832 | Lim et al. | Sep 2015 | S |
| D738901 | Amin | Sep 2015 | S |
| D740301 | Soegiono et al. | Oct 2015 | S |
| D740308 | Kim et al. | Oct 2015 | S |
| D740311 | Drozd et al. | Oct 2015 | S |
| D741354 | Lee et al. | Oct 2015 | S |
| D741359 | Ji-Hye et al. | Oct 2015 | S |
| 9149233 | Kamath et al. | Oct 2015 | B2 |
| 9155843 | Brauker et al. | Oct 2015 | B2 |
| 9171343 | Fischell et al. | Oct 2015 | B1 |
| D743431 | Pal et al. | Nov 2015 | S |
| D743991 | Pal et al. | Nov 2015 | S |
| 9180224 | Moseley et al. | Nov 2015 | B2 |
| 9180244 | Anderson et al. | Nov 2015 | B2 |
| 9192716 | Jugl et al. | Nov 2015 | B2 |
| D744514 | Shin et al. | Dec 2015 | S |
| D744517 | Pal et al. | Dec 2015 | S |
| D745032 | Pal et al. | Dec 2015 | S |
| D745034 | Pal et al. | Dec 2015 | S |
| D745035 | Pal et al. | Dec 2015 | S |
| D746827 | Jung et al. | Jan 2016 | S |
| D746828 | Arai et al. | Jan 2016 | S |
| D747352 | Lee et al. | Jan 2016 | S |
| 9233204 | Booth et al. | Jan 2016 | B2 |
| D749097 | Zou et al. | Feb 2016 | S |
| D749118 | Wang | Feb 2016 | S |
| 9247901 | Kamath et al. | Feb 2016 | B2 |
| D751100 | Lindn et al. | Mar 2016 | S |
| D752604 | Zhang | Mar 2016 | S |
| D753134 | Vazquez | Apr 2016 | S |
| D754718 | Zhou | Apr 2016 | S |
| 9314566 | Wenger et al. | Apr 2016 | B2 |
| 9320471 | Hayes et al. | Apr 2016 | B2 |
| D755193 | Sun et al. | May 2016 | S |
| D755799 | Finnis et al. | May 2016 | S |
| D755820 | Wang | May 2016 | S |
| D756387 | Chang et al. | May 2016 | S |
| D757032 | Sabia et al. | May 2016 | S |
| D757035 | Raskin et al. | May 2016 | S |
| 9333298 | Kim et al. | May 2016 | B2 |
| D758391 | Suarez | Jun 2016 | S |
| D758422 | Zhao | Jun 2016 | S |
| D759032 | Amin et al. | Jun 2016 | S |
| D759078 | Iwamoto | Jun 2016 | S |
| D759678 | Jung et al. | Jun 2016 | S |
| D759687 | Chang et al. | Jun 2016 | S |
| D761812 | Motamedi | Jul 2016 | S |
| D763308 | Wang et al. | Aug 2016 | S |
| D763868 | Lee et al. | Aug 2016 | S |
| D765110 | Liang | Aug 2016 | S |
| D765124 | Minks-Brown et al. | Aug 2016 | S |
| 9402950 | Dilanni et al. | Aug 2016 | B2 |
| 9415157 | Mann et al. | Aug 2016 | B2 |
| D765707 | Gomez | Sep 2016 | S |
| D766286 | Lee et al. | Sep 2016 | S |
| D767586 | Kwon et al. | Sep 2016 | S |
| D768154 | Kim et al. | Oct 2016 | S |
| D768188 | Li et al. | Oct 2016 | S |
| D768660 | Wielgosz | Oct 2016 | S |
| D768685 | Lee et al. | Oct 2016 | S |
| D769315 | Scotti | Oct 2016 | S |
| 9474855 | McCann et al. | Oct 2016 | B2 |
| D770507 | Umezawa et al. | Nov 2016 | S |
| D770515 | Cho et al. | Nov 2016 | S |
| D771073 | Choi et al. | Nov 2016 | S |
| D771076 | Butcher et al. | Nov 2016 | S |
| D771690 | Yin et al. | Nov 2016 | S |
| D772911 | Lee et al. | Nov 2016 | S |
| 9480796 | Starkweather et al. | Nov 2016 | B2 |
| 9486172 | Cobelli et al. | Nov 2016 | B2 |
| 9486571 | Rosinko | Nov 2016 | B2 |
| 9486578 | Finan et al. | Nov 2016 | B2 |
| D773531 | Toth et al. | Dec 2016 | S |
| D775184 | Song et al. | Dec 2016 | S |
| D775196 | Huang et al. | Dec 2016 | S |
| 9520649 | De Rochemont | Dec 2016 | B2 |
| D775658 | Luo et al. | Jan 2017 | S |
| D776126 | Lai et al. | Jan 2017 | S |
| D776687 | Wick et al. | Jan 2017 | S |
| D777191 | Polimeni | Jan 2017 | S |
| D777758 | Kisselev et al. | Jan 2017 | S |
| 9561324 | Estes | Feb 2017 | B2 |
| 9579456 | Budiman et al. | Feb 2017 | B2 |
| D781323 | Green et al. | Mar 2017 | S |
| D781781 | Schimmoeller, Jr. | Mar 2017 | S |
| D781877 | Ko et al. | Mar 2017 | S |
| D781878 | Butcher et al. | Mar 2017 | S |
| D781879 | Butcher et al. | Mar 2017 | S |
| D781903 | Reichle et al. | Mar 2017 | S |
| D781905 | Nakaguchi et al. | Mar 2017 | S |
| D782506 | Kim et al. | Mar 2017 | S |
| D783672 | Rajasankar et al. | Apr 2017 | S |
| D785010 | Bachman et al. | Apr 2017 | S |
| D785656 | Bramer et al. | May 2017 | S |
| D786278 | Motamedi | May 2017 | S |
| D786898 | Hall | May 2017 | S |
| D788126 | Evnin et al. | May 2017 | S |
| 9656017 | Greene | May 2017 | B2 |
| D788621 | Shallice et al. | Jun 2017 | S |
| D788652 | Mutsuro et al. | Jun 2017 | S |
| D789402 | Dye et al. | Jun 2017 | S |
| D789967 | Kaplan et al. | Jun 2017 | S |
| D789982 | Christiana et al. | Jun 2017 | S |
| D790560 | Inose et al. | Jun 2017 | S |
| D791781 | Donarski et al. | Jul 2017 | S |
| D791805 | Segars | Jul 2017 | S |
| D791812 | Bistoni et al. | Jul 2017 | S |
| D793412 | Chaudhri et al. | Aug 2017 | S |
| D795886 | Ng et al. | Aug 2017 | S |
| D795891 | Kohan et al. | Aug 2017 | S |
| D795900 | Bischoff et al. | Aug 2017 | S |
| D795906 | Butrick | Aug 2017 | S |
| D795927 | Bischoff et al. | Aug 2017 | S |
| 9743224 | San et al. | Aug 2017 | B2 |
| D796530 | McMillan et al. | Sep 2017 | S |
| D796540 | McLean et al. | Sep 2017 | S |
| D797116 | Chapman et al. | Sep 2017 | S |
| D797763 | Kim et al. | Sep 2017 | S |
| D797774 | Park et al. | Sep 2017 | S |
| D797797 | Gandhi et al. | Sep 2017 | S |
| D798310 | Golden et al. | Sep 2017 | S |
| D798311 | Golden et al. | Sep 2017 | S |
| D799536 | Eder | Oct 2017 | S |
| D800765 | Stoksik | Oct 2017 | S |
| D800769 | Hennessy et al. | Oct 2017 | S |
| D801383 | Park et al. | Oct 2017 | S |
| D802011 | Friedman et al. | Nov 2017 | S |
| D802088 | Bos et al. | Nov 2017 | S |
| D803232 | Leigh et al. | Nov 2017 | S |
| D803242 | Mizono et al. | Nov 2017 | S |
| D804502 | Amini et al. | Dec 2017 | S |
| D805525 | Dascola et al. | Dec 2017 | S |
| D806716 | Pahwa et al. | Jan 2018 | S |
| D807376 | Mizono et al. | Jan 2018 | S |
| D807400 | LaGreca | Jan 2018 | S |
| D807910 | Graham et al. | Jan 2018 | S |
| D807918 | Cohen et al. | Jan 2018 | S |
| D807919 | Cohen et al. | Jan 2018 | S |
| D808423 | Jiang et al. | Jan 2018 | S |
| D808974 | Chiappone et al. | Jan 2018 | S |
| D808983 | Narinedhat et al. | Jan 2018 | S |
| 9857090 | Golden et al. | Jan 2018 | B2 |
| 9878097 | Estes | Jan 2018 | B2 |
| D810116 | McLean et al. | Feb 2018 | S |
| D810771 | Gandhi et al. | Feb 2018 | S |
| 9889254 | Haenggi | Feb 2018 | B2 |
| 9907515 | Doyle et al. | Mar 2018 | B2 |
| D815131 | Thompson et al. | Apr 2018 | S |
| D816090 | Stonecipher et al. | Apr 2018 | S |
| D817339 | Nanjappan et al. | May 2018 | S |
| D818491 | Timmer et al. | May 2018 | S |
| D819057 | Huang | May 2018 | S |
| D819059 | O'Toole | May 2018 | S |
| 9968729 | Estes | May 2018 | B2 |
| 9980140 | Spencer et al. | May 2018 | B1 |
| 9984773 | Gondhalekar et al. | May 2018 | B2 |
| D820311 | Cabrera et al. | Jun 2018 | S |
| D820862 | Alfonzo et al. | Jun 2018 | S |
| D822034 | Clymer et al. | Jul 2018 | S |
| D822677 | Weaver et al. | Jul 2018 | S |
| D822684 | Clausen-Stuck et al. | Jul 2018 | S |
| D822692 | Loychik et al. | Jul 2018 | S |
| D823862 | Chung et al. | Jul 2018 | S |
| D824400 | Chang et al. | Jul 2018 | S |
| D824951 | Kolbrener et al. | Aug 2018 | S |
| D826956 | Pillalamarri et al. | Aug 2018 | S |
| D826957 | Pillalamarri et al. | Aug 2018 | S |
| D828381 | Lee et al. | Sep 2018 | S |
| D829732 | Jeffrey et al. | Oct 2018 | S |
| D830374 | Leonard et al. | Oct 2018 | S |
| D830384 | Lepine et al. | Oct 2018 | S |
| D830385 | Lepine et al. | Oct 2018 | S |
| D830407 | Kisielius et al. | Oct 2018 | S |
| D831033 | Leonard et al. | Oct 2018 | S |
| D833469 | Coleman et al. | Nov 2018 | S |
| D834601 | Felt | Nov 2018 | S |
| D835132 | Ito et al. | Dec 2018 | S |
| D835145 | Cashner et al. | Dec 2018 | S |
| D835147 | Kisielius et al. | Dec 2018 | S |
| D835651 | Bao | Dec 2018 | S |
| D835666 | Saleh et al. | Dec 2018 | S |
| D836123 | Pillalamarri et al. | Dec 2018 | S |
| D837807 | Baber et al. | Jan 2019 | S |
| D838731 | Pillalamarri et al. | Jan 2019 | S |
| D840418 | Saad et al. | Feb 2019 | S |
| D840419 | Saad et al. | Feb 2019 | S |
| D844022 | Amin | Mar 2019 | S |
| D845317 | Wellmeier et al. | Apr 2019 | S |
| 10248839 | Levy et al. | Apr 2019 | B2 |
| D848459 | Li | May 2019 | S |
| D851099 | Uppala et al. | Jun 2019 | S |
| D851658 | Pillalamarri et al. | Jun 2019 | S |
| 10335464 | Michelich et al. | Jul 2019 | B1 |
| 10449294 | Estes | Oct 2019 | B1 |
| D865795 | Koo | Nov 2019 | S |
| D872746 | LaBorde | Jan 2020 | S |
| 10545132 | Guthrie | Jan 2020 | B2 |
| D874471 | Pillalamarri et al. | Feb 2020 | S |
| D875114 | Clediere | Feb 2020 | S |
| 10569015 | Estes | Feb 2020 | B2 |
| 10583250 | Mazlish et al. | Mar 2020 | B2 |
| D880498 | Shahidi et al. | Apr 2020 | S |
| D888070 | Yusupov et al. | Jun 2020 | S |
| 10737015 | Estes | Aug 2020 | B2 |
| 10737024 | Schmid | Aug 2020 | B2 |
| D904426 | Paul | Dec 2020 | S |
| D911353 | Sanchez et al. | Feb 2021 | S |
| D914031 | Ding et al. | Mar 2021 | S |
| D916729 | Gabriel et al. | Apr 2021 | S |
| D916870 | Hemsley | Apr 2021 | S |
| D916878 | Kim et al. | Apr 2021 | S |
| 10987468 | Mazlish et al. | Apr 2021 | B2 |
| D918261 | Ramamurthy et al. | May 2021 | S |
| D920351 | Zhang | May 2021 | S |
| D923033 | Smith et al. | Jun 2021 | S |
| D927533 | Clymer | Aug 2021 | S |
| 11147914 | Estes | Oct 2021 | B2 |
| D938447 | Holland | Dec 2021 | S |
| 11197964 | Sjolund et al. | Dec 2021 | B2 |
| 11260169 | Estes | Mar 2022 | B2 |
| D954078 | Rahate et al. | Jun 2022 | S |
| 20010003542 | Kita | Jun 2001 | A1 |
| 20010021803 | Blank et al. | Sep 2001 | A1 |
| 20010034023 | Stanton et al. | Oct 2001 | A1 |
| 20010034502 | Moberg et al. | Oct 2001 | A1 |
| 20010041869 | Causey et al. | Nov 2001 | A1 |
| 20010048969 | Constantino et al. | Dec 2001 | A1 |
| 20010051377 | Hammer et al. | Dec 2001 | A1 |
| 20010053895 | Vaillancourt | Dec 2001 | A1 |
| 20010056258 | Evans | Dec 2001 | A1 |
| 20010056262 | Cabiri et al. | Dec 2001 | A1 |
| 20020010401 | Bushmakin et al. | Jan 2002 | A1 |
| 20020010423 | Gross et al. | Jan 2002 | A1 |
| 20020013784 | Swanson | Jan 2002 | A1 |
| 20020016534 | Trepagnier et al. | Feb 2002 | A1 |
| 20020016568 | Lebel et al. | Feb 2002 | A1 |
| 20020032402 | Daoud et al. | Mar 2002 | A1 |
| 20020040208 | Flaherty et al. | Apr 2002 | A1 |
| 20020046315 | Miller et al. | Apr 2002 | A1 |
| 20020047768 | Duffy | Apr 2002 | A1 |
| 20020055845 | Ueda et al. | May 2002 | A1 |
| 20020070983 | Kozub et al. | Jun 2002 | A1 |
| 20020072720 | Hague et al. | Jun 2002 | A1 |
| 20020123740 | Flaherty et al. | Sep 2002 | A1 |
| 20020128543 | Leonhardt | Sep 2002 | A1 |
| 20020147423 | Burbank et al. | Oct 2002 | A1 |
| 20020155425 | Han et al. | Oct 2002 | A1 |
| 20020156462 | Stultz | Oct 2002 | A1 |
| 20020161288 | Shin et al. | Oct 2002 | A1 |
| 20020164973 | Janik et al. | Nov 2002 | A1 |
| 20020173769 | Gray et al. | Nov 2002 | A1 |
| 20020190818 | Endou et al. | Dec 2002 | A1 |
| 20030023148 | Lorenz et al. | Jan 2003 | A1 |
| 20030023152 | Abbink et al. | Jan 2003 | A1 |
| 20030034124 | Sugaya et al. | Feb 2003 | A1 |
| 20030040715 | D'Antonio et al. | Feb 2003 | A1 |
| 20030050621 | Lebel et al. | Mar 2003 | A1 |
| 20030055380 | Flaherty | Mar 2003 | A1 |
| 20030060692 | L. Ruchti et al. | Mar 2003 | A1 |
| 20030065308 | Lebel et al. | Apr 2003 | A1 |
| 20030086073 | Braig et al. | May 2003 | A1 |
| 20030086074 | Braig et al. | May 2003 | A1 |
| 20030086075 | Braig et al. | May 2003 | A1 |
| 20030088238 | Poulsen et al. | May 2003 | A1 |
| 20030090649 | Sterling et al. | May 2003 | A1 |
| 20030100040 | Bonnecaze et al. | May 2003 | A1 |
| 20030104982 | Wittmann et al. | Jun 2003 | A1 |
| 20030121055 | Kaminski et al. | Jun 2003 | A1 |
| 20030122647 | Ou | Jul 2003 | A1 |
| 20030125672 | Adair et al. | Jul 2003 | A1 |
| 20030135388 | Martucci et al. | Jul 2003 | A1 |
| 20030144582 | Cohen et al. | Jul 2003 | A1 |
| 20030148024 | Kodas et al. | Aug 2003 | A1 |
| 20030161744 | Vilks et al. | Aug 2003 | A1 |
| 20030163097 | Fleury et al. | Aug 2003 | A1 |
| 20030170436 | Sumi et al. | Sep 2003 | A1 |
| 20030175806 | Rule et al. | Sep 2003 | A1 |
| 20030195404 | Knobbe et al. | Oct 2003 | A1 |
| 20030198558 | Nason et al. | Oct 2003 | A1 |
| 20030208113 | Mault et al. | Nov 2003 | A1 |
| 20030208154 | Close et al. | Nov 2003 | A1 |
| 20030212379 | Bylund et al. | Nov 2003 | A1 |
| 20030216627 | Lorenz et al. | Nov 2003 | A1 |
| 20030216683 | Shekalim | Nov 2003 | A1 |
| 20030216686 | Lynch et al. | Nov 2003 | A1 |
| 20030220605 | Bowman et al. | Nov 2003 | A1 |
| 20030221621 | Pokharna et al. | Dec 2003 | A1 |
| 20030236498 | Gross et al. | Dec 2003 | A1 |
| 20040001027 | Killen et al. | Jan 2004 | A1 |
| 20040006316 | Patton | Jan 2004 | A1 |
| 20040010207 | Flaherty et al. | Jan 2004 | A1 |
| 20040019325 | Shekalim | Jan 2004 | A1 |
| 20040034295 | Salganicoff | Feb 2004 | A1 |
| 20040045879 | Shults et al. | Mar 2004 | A1 |
| 20040051368 | Caputo et al. | Mar 2004 | A1 |
| 20040064088 | Gorman et al. | Apr 2004 | A1 |
| 20040064096 | Flaherty et al. | Apr 2004 | A1 |
| 20040064259 | Haaland et al. | Apr 2004 | A1 |
| 20040068224 | Couvillon et al. | Apr 2004 | A1 |
| 20040068230 | Estes et al. | Apr 2004 | A1 |
| 20040069004 | Gist et al. | Apr 2004 | A1 |
| 20040069044 | Lavi et al. | Apr 2004 | A1 |
| 20040078028 | Flaherty et al. | Apr 2004 | A1 |
| 20040087894 | Flaherty | May 2004 | A1 |
| 20040087904 | Langley et al. | May 2004 | A1 |
| 20040092865 | Flaherty et al. | May 2004 | A1 |
| 20040092878 | Flaherty | May 2004 | A1 |
| 20040097796 | Berman et al. | May 2004 | A1 |
| 20040115068 | Hansen et al. | Jun 2004 | A1 |
| 20040116847 | Wall | Jun 2004 | A1 |
| 20040116866 | Gorman et al. | Jun 2004 | A1 |
| 20040122353 | Shahmirian et al. | Jun 2004 | A1 |
| 20040127844 | Flaherty | Jul 2004 | A1 |
| 20040133166 | Moberg et al. | Jul 2004 | A1 |
| 20040147034 | Gore et al. | Jul 2004 | A1 |
| 20040153032 | Garribotto et al. | Aug 2004 | A1 |
| 20040158207 | Hunn et al. | Aug 2004 | A1 |
| 20040171983 | Sparks et al. | Sep 2004 | A1 |
| 20040176720 | Kipfer | Sep 2004 | A1 |
| 20040176727 | Shekalim | Sep 2004 | A1 |
| 20040187952 | Jones | Sep 2004 | A1 |
| 20040203357 | Nassimi | Oct 2004 | A1 |
| 20040204673 | Flaherty | Oct 2004 | A1 |
| 20040204744 | Penner et al. | Oct 2004 | A1 |
| 20040204868 | Maynard et al. | Oct 2004 | A1 |
| 20040215492 | Choi | Oct 2004 | A1 |
| 20040220551 | Flaherty et al. | Nov 2004 | A1 |
| 20040235446 | Flaherty et al. | Nov 2004 | A1 |
| 20040241736 | Hendee et al. | Dec 2004 | A1 |
| 20040249308 | Forssell | Dec 2004 | A1 |
| 20040260233 | Garibotto et al. | Dec 2004 | A1 |
| 20050003470 | Nelson et al. | Jan 2005 | A1 |
| 20050010165 | Hickle | Jan 2005 | A1 |
| 20050020980 | Inoue et al. | Jan 2005 | A1 |
| 20050021005 | Flaherty et al. | Jan 2005 | A1 |
| 20050021104 | DiLorenzo | Jan 2005 | A1 |
| 20050022274 | Campbell et al. | Jan 2005 | A1 |
| 20050033148 | Haueter et al. | Feb 2005 | A1 |
| 20050038332 | Saidara et al. | Feb 2005 | A1 |
| 20050049179 | Davidson et al. | Mar 2005 | A1 |
| 20050065464 | Talbot et al. | Mar 2005 | A1 |
| 20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
| 20050075624 | Miesel | Apr 2005 | A1 |
| 20050090808 | Malave et al. | Apr 2005 | A1 |
| 20050090851 | Devlin | Apr 2005 | A1 |
| 20050095063 | Fathallah et al. | May 2005 | A1 |
| 20050101933 | Marrs et al. | May 2005 | A1 |
| 20050105095 | Pesach et al. | May 2005 | A1 |
| 20050107743 | Fangrow | May 2005 | A1 |
| 20050113745 | Stultz | May 2005 | A1 |
| 20050124866 | Elaz et al. | Jun 2005 | A1 |
| 20050134609 | Yu | Jun 2005 | A1 |
| 20050137530 | Campbell et al. | Jun 2005 | A1 |
| 20050137573 | McLaughlin | Jun 2005 | A1 |
| 20050160858 | Mernoe | Jul 2005 | A1 |
| 20050171503 | Van et al. | Aug 2005 | A1 |
| 20050171512 | Flaherty | Aug 2005 | A1 |
| 20050182306 | Sloan | Aug 2005 | A1 |
| 20050182366 | Vogt et al. | Aug 2005 | A1 |
| 20050192494 | Ginsberg | Sep 2005 | A1 |
| 20050192557 | Brauker et al. | Sep 2005 | A1 |
| 20050197621 | Poulsen et al. | Sep 2005 | A1 |
| 20050203360 | Brauker et al. | Sep 2005 | A1 |
| 20050203461 | Flaherty et al. | Sep 2005 | A1 |
| 20050215982 | Malave et al. | Sep 2005 | A1 |
| 20050222645 | Malave et al. | Oct 2005 | A1 |
| 20050234404 | Vilks et al. | Oct 2005 | A1 |
| 20050238507 | Diianni et al. | Oct 2005 | A1 |
| 20050240544 | Kil et al. | Oct 2005 | A1 |
| 20050245878 | Mernoe et al. | Nov 2005 | A1 |
| 20050251097 | Mernoe | Nov 2005 | A1 |
| 20050261660 | Choi | Nov 2005 | A1 |
| 20050262451 | Remignanti et al. | Nov 2005 | A1 |
| 20050267402 | Stewart et al. | Dec 2005 | A1 |
| 20050272640 | Doyle et al. | Dec 2005 | A1 |
| 20050273059 | Mernoe et al. | Dec 2005 | A1 |
| 20050277890 | Stewart et al. | Dec 2005 | A1 |
| 20050277912 | John | Dec 2005 | A1 |
| 20060009727 | O'Mahony et al. | Jan 2006 | A1 |
| 20060036214 | Mogensen et al. | Feb 2006 | A1 |
| 20060041229 | Garibotto et al. | Feb 2006 | A1 |
| 20060042633 | Bishop et al. | Mar 2006 | A1 |
| 20060064053 | Bollish et al. | Mar 2006 | A1 |
| 20060069351 | Safabash et al. | Mar 2006 | A9 |
| 20060069382 | Pedersen | Mar 2006 | A1 |
| 20060074381 | Malave et al. | Apr 2006 | A1 |
| 20060075269 | Liong et al. | Apr 2006 | A1 |
| 20060079765 | Neer et al. | Apr 2006 | A1 |
| 20060079809 | Goldberger et al. | Apr 2006 | A1 |
| 20060086994 | Mefers et al. | Apr 2006 | A1 |
| 20060095014 | Ethelfeld | May 2006 | A1 |
| 20060100494 | Kroll | May 2006 | A1 |
| 20060125654 | Liao et al. | Jun 2006 | A1 |
| 20060134323 | O'Brien | Jun 2006 | A1 |
| 20060134491 | Hilchenko et al. | Jun 2006 | A1 |
| 20060135913 | Ethelfeld | Jun 2006 | A1 |
| 20060142698 | Ethelfeld | Jun 2006 | A1 |
| 20060151545 | Imhof et al. | Jul 2006 | A1 |
| 20060167350 | Monfre et al. | Jul 2006 | A1 |
| 20060173410 | Moberg et al. | Aug 2006 | A1 |
| 20060178633 | Garibotto et al. | Aug 2006 | A1 |
| 20060184104 | Cheney et al. | Aug 2006 | A1 |
| 20060184119 | Remde et al. | Aug 2006 | A1 |
| 20060189925 | Gable et al. | Aug 2006 | A1 |
| 20060189926 | Hall et al. | Aug 2006 | A1 |
| 20060197015 | Sterling et al. | Sep 2006 | A1 |
| 20060200070 | Callicoat et al. | Sep 2006 | A1 |
| 20060200073 | Radmer et al. | Sep 2006 | A1 |
| 20060204535 | Johnson | Sep 2006 | A1 |
| 20060206054 | Shekalim | Sep 2006 | A1 |
| 20060214511 | Dayan | Sep 2006 | A1 |
| 20060229531 | Goldberger et al. | Oct 2006 | A1 |
| 20060247574 | Maule et al. | Nov 2006 | A1 |
| 20060247581 | Pedersen et al. | Nov 2006 | A1 |
| 20060253085 | Geismar et al. | Nov 2006 | A1 |
| 20060253086 | Moberg et al. | Nov 2006 | A1 |
| 20060258973 | Volt | Nov 2006 | A1 |
| 20060258976 | Shturman et al. | Nov 2006 | A1 |
| 20060264835 | Nielsen et al. | Nov 2006 | A1 |
| 20060264890 | Moberg et al. | Nov 2006 | A1 |
| 20060264894 | Moberg et al. | Nov 2006 | A1 |
| 20060264895 | Flanders | Nov 2006 | A1 |
| 20060270983 | Lord et al. | Nov 2006 | A1 |
| 20060276771 | Galley et al. | Dec 2006 | A1 |
| 20060282290 | Flaherty et al. | Dec 2006 | A1 |
| 20070016127 | Staib et al. | Jan 2007 | A1 |
| 20070060796 | Kim | Mar 2007 | A1 |
| 20070060869 | Tolle et al. | Mar 2007 | A1 |
| 20070060870 | Tolle et al. | Mar 2007 | A1 |
| 20070060872 | Hall et al. | Mar 2007 | A1 |
| 20070073228 | Mernoe et al. | Mar 2007 | A1 |
| 20070073235 | Estes et al. | Mar 2007 | A1 |
| 20070073236 | Mernoe et al. | Mar 2007 | A1 |
| 20070078818 | Zivitz et al. | Apr 2007 | A1 |
| 20070079836 | Reghabi et al. | Apr 2007 | A1 |
| 20070083160 | Hall et al. | Apr 2007 | A1 |
| 20070088271 | Richards | Apr 2007 | A1 |
| 20070093750 | Jan et al. | Apr 2007 | A1 |
| 20070093786 | Goldsmith et al. | Apr 2007 | A1 |
| 20070100222 | Mastrototaro et al. | May 2007 | A1 |
| 20070100635 | Mahajan et al. | May 2007 | A1 |
| 20070106135 | Sloan et al. | May 2007 | A1 |
| 20070106218 | Yodfat et al. | May 2007 | A1 |
| 20070112298 | Mueller et al. | May 2007 | A1 |
| 20070116601 | Patton | May 2007 | A1 |
| 20070118364 | Wise et al. | May 2007 | A1 |
| 20070118405 | Campbell et al. | May 2007 | A1 |
| 20070123819 | Mernoe et al. | May 2007 | A1 |
| 20070124002 | Estes et al. | May 2007 | A1 |
| 20070129690 | Rosenblatt et al. | Jun 2007 | A1 |
| 20070142720 | Ridder et al. | Jun 2007 | A1 |
| 20070142776 | Kovelman et al. | Jun 2007 | A9 |
| 20070155307 | Ng et al. | Jul 2007 | A1 |
| 20070156092 | Estes et al. | Jul 2007 | A1 |
| 20070156094 | Safabash et al. | Jul 2007 | A1 |
| 20070166170 | Nason et al. | Jul 2007 | A1 |
| 20070166453 | Van et al. | Jul 2007 | A1 |
| 20070167905 | Estes et al. | Jul 2007 | A1 |
| 20070169607 | Keller et al. | Jul 2007 | A1 |
| 20070173761 | Kanderian et al. | Jul 2007 | A1 |
| 20070173974 | Lin | Jul 2007 | A1 |
| 20070179352 | Randlov et al. | Aug 2007 | A1 |
| 20070191702 | Yodfat et al. | Aug 2007 | A1 |
| 20070191716 | Goldberger et al. | Aug 2007 | A1 |
| 20070197163 | Robertson | Aug 2007 | A1 |
| 20070219432 | Thompson | Sep 2007 | A1 |
| 20070219480 | Kamen et al. | Sep 2007 | A1 |
| 20070225675 | Robinson et al. | Sep 2007 | A1 |
| 20070233521 | Wehba et al. | Oct 2007 | A1 |
| 20070239116 | Follman et al. | Oct 2007 | A1 |
| 20070244381 | Robinson et al. | Oct 2007 | A1 |
| 20070248238 | Abreu | Oct 2007 | A1 |
| 20070249007 | Rosero | Oct 2007 | A1 |
| 20070252774 | Ql et al. | Nov 2007 | A1 |
| 20070255250 | Moberg et al. | Nov 2007 | A1 |
| 20070259768 | Kear et al. | Nov 2007 | A1 |
| 20070264707 | Liederman et al. | Nov 2007 | A1 |
| 20070282269 | Carter et al. | Dec 2007 | A1 |
| 20070282299 | Hellwig | Dec 2007 | A1 |
| 20070287931 | Dilorenzo | Dec 2007 | A1 |
| 20070287985 | Estes et al. | Dec 2007 | A1 |
| 20070293843 | Ireland et al. | Dec 2007 | A1 |
| 20080009824 | Moberg et al. | Jan 2008 | A1 |
| 20080015422 | Wessel | Jan 2008 | A1 |
| 20080027574 | Thomas | Jan 2008 | A1 |
| 20080031481 | Warren et al. | Feb 2008 | A1 |
| 20080033272 | Gough et al. | Feb 2008 | A1 |
| 20080033320 | Racchini et al. | Feb 2008 | A1 |
| 20080045891 | Maule et al. | Feb 2008 | A1 |
| 20080051697 | Mounce et al. | Feb 2008 | A1 |
| 20080051698 | Mounce et al. | Feb 2008 | A1 |
| 20080051714 | Moberg et al. | Feb 2008 | A1 |
| 20080051716 | Stutz | Feb 2008 | A1 |
| 20080051730 | Bikovsky | Feb 2008 | A1 |
| 20080051738 | Griffin | Feb 2008 | A1 |
| 20080051764 | Dent et al. | Feb 2008 | A1 |
| 20080058625 | McGarraugh et al. | Mar 2008 | A1 |
| 20080065050 | Sparks et al. | Mar 2008 | A1 |
| 20080071157 | McGarraugh et al. | Mar 2008 | A1 |
| 20080071158 | McGarraugh et al. | Mar 2008 | A1 |
| 20080077081 | Mounce et al. | Mar 2008 | A1 |
| 20080078400 | Martens et al. | Apr 2008 | A1 |
| 20080097289 | Steil et al. | Apr 2008 | A1 |
| 20080097326 | Moberg et al. | Apr 2008 | A1 |
| 20080097375 | Bikovsky | Apr 2008 | A1 |
| 20080097381 | Moberg et al. | Apr 2008 | A1 |
| 20080103022 | Dvorak et al. | May 2008 | A1 |
| 20080109050 | John | May 2008 | A1 |
| 20080114304 | Nalesso et al. | May 2008 | A1 |
| 20080125700 | Moberg et al. | May 2008 | A1 |
| 20080125701 | Moberg et al. | May 2008 | A1 |
| 20080129535 | Thompson et al. | Jun 2008 | A1 |
| 20080132880 | Buchman | Jun 2008 | A1 |
| 20080160492 | Campbell et al. | Jul 2008 | A1 |
| 20080161664 | Mastrototaro et al. | Jul 2008 | A1 |
| 20080172026 | Blomquist | Jul 2008 | A1 |
| 20080172027 | Blomquist | Jul 2008 | A1 |
| 20080172028 | Blomquist | Jul 2008 | A1 |
| 20080172029 | Blomquist | Jul 2008 | A1 |
| 20080177149 | Weinert et al. | Jul 2008 | A1 |
| 20080183060 | Steil et al. | Jul 2008 | A1 |
| 20080188796 | Steil et al. | Aug 2008 | A1 |
| 20080198012 | Kamen | Aug 2008 | A1 |
| 20080200838 | Goldberger et al. | Aug 2008 | A1 |
| 20080201325 | Doniger et al. | Aug 2008 | A1 |
| 20080206067 | De et al. | Aug 2008 | A1 |
| 20080208113 | Damiano et al. | Aug 2008 | A1 |
| 20080208627 | Skyggebjerg | Aug 2008 | A1 |
| 20080214919 | Harmon et al. | Sep 2008 | A1 |
| 20080215035 | Yodfat et al. | Sep 2008 | A1 |
| 20080228056 | Blomquist et al. | Sep 2008 | A1 |
| 20080234630 | Iddan et al. | Sep 2008 | A1 |
| 20080249386 | Besterman et al. | Oct 2008 | A1 |
| 20080255516 | Yodfat et al. | Oct 2008 | A1 |
| 20080269585 | Ginsberg | Oct 2008 | A1 |
| 20080269683 | Bikovsky | Oct 2008 | A1 |
| 20080269687 | Chong et al. | Oct 2008 | A1 |
| 20080269714 | Mastrototaro et al. | Oct 2008 | A1 |
| 20080269723 | Mastrototaro et al. | Oct 2008 | A1 |
| 20080287906 | Burkholz et al. | Nov 2008 | A1 |
| 20080294094 | Mhatre et al. | Nov 2008 | A1 |
| 20080294109 | Estes et al. | Nov 2008 | A1 |
| 20080294142 | Patel et al. | Nov 2008 | A1 |
| 20080300572 | Rankers et al. | Dec 2008 | A1 |
| 20080306434 | Dobbles et al. | Dec 2008 | A1 |
| 20080306444 | Brister et al. | Dec 2008 | A1 |
| 20080312512 | Brukalo et al. | Dec 2008 | A1 |
| 20080312634 | Helmerson et al. | Dec 2008 | A1 |
| 20080319381 | Yodfat et al. | Dec 2008 | A1 |
| 20080319383 | Byland et al. | Dec 2008 | A1 |
| 20080319384 | Yodfat et al. | Dec 2008 | A1 |
| 20080319394 | Yodfat et al. | Dec 2008 | A1 |
| 20080319414 | Yodfat et al. | Dec 2008 | A1 |
| 20080319416 | Yodfat et al. | Dec 2008 | A1 |
| 20090006061 | Thukral et al. | Jan 2009 | A1 |
| 20090018406 | Yodfat et al. | Jan 2009 | A1 |
| 20090030398 | Yodfat et al. | Jan 2009 | A1 |
| 20090036753 | King | Feb 2009 | A1 |
| 20090036760 | Hayter | Feb 2009 | A1 |
| 20090036870 | Mounce et al. | Feb 2009 | A1 |
| 20090043240 | Robinson et al. | Feb 2009 | A1 |
| 20090043291 | Thompson | Feb 2009 | A1 |
| 20090048584 | Thompson | Feb 2009 | A1 |
| 20090054753 | Robinson et al. | Feb 2009 | A1 |
| 20090069743 | Krishnamoorthy et al. | Mar 2009 | A1 |
| 20090069745 | Estes et al. | Mar 2009 | A1 |
| 20090069746 | Miller et al. | Mar 2009 | A1 |
| 20090069749 | Miller et al. | Mar 2009 | A1 |
| 20090069784 | Estes et al. | Mar 2009 | A1 |
| 20090069785 | Miller et al. | Mar 2009 | A1 |
| 20090069787 | Estes et al. | Mar 2009 | A1 |
| 20090076453 | Mejlhede et al. | Mar 2009 | A1 |
| 20090076849 | Diller | Mar 2009 | A1 |
| 20090082728 | Bikovsky | Mar 2009 | A1 |
| 20090093756 | Minaie et al. | Apr 2009 | A1 |
| 20090099507 | Koops | Apr 2009 | A1 |
| 20090099521 | Gravesen et al. | Apr 2009 | A1 |
| 20090105573 | Malecha | Apr 2009 | A1 |
| 20090105636 | Hayter et al. | Apr 2009 | A1 |
| 20090112333 | Sahai | Apr 2009 | A1 |
| 20090118664 | Estes et al. | May 2009 | A1 |
| 20090131861 | Braig et al. | May 2009 | A1 |
| 20090143916 | Boll et al. | Jun 2009 | A1 |
| 20090156922 | Goldberger et al. | Jun 2009 | A1 |
| 20090156924 | Shariati et al. | Jun 2009 | A1 |
| 20090156990 | Wenger et al. | Jun 2009 | A1 |
| 20090163781 | Say et al. | Jun 2009 | A1 |
| 20090164190 | Hayter | Jun 2009 | A1 |
| 20090177142 | Blomquist et al. | Jul 2009 | A1 |
| 20090177154 | Blomquist | Jul 2009 | A1 |
| 20090192722 | Shariati et al. | Jul 2009 | A1 |
| 20090198191 | Chong et al. | Aug 2009 | A1 |
| 20090198215 | Chong et al. | Aug 2009 | A1 |
| 20090198350 | Thiele | Aug 2009 | A1 |
| 20090212966 | Panduro | Aug 2009 | A1 |
| 20090221890 | Saffer et al. | Sep 2009 | A1 |
| 20090228214 | Say et al. | Sep 2009 | A1 |
| 20090275887 | Estes | Nov 2009 | A1 |
| 20090318791 | Kaastrup | Dec 2009 | A1 |
| 20090326343 | Gable et al. | Dec 2009 | A1 |
| 20090326472 | Carter et al. | Dec 2009 | A1 |
| 20100010330 | Rankers et al. | Jan 2010 | A1 |
| 20100017141 | Campbell et al. | Jan 2010 | A1 |
| 20100036326 | Matusch | Feb 2010 | A1 |
| 20100057040 | Hayter | Mar 2010 | A1 |
| 20100057041 | Hayter | Mar 2010 | A1 |
| 20100064243 | Buck et al. | Mar 2010 | A1 |
| 20100077198 | Buck et al. | Mar 2010 | A1 |
| 20100094078 | Weston | Apr 2010 | A1 |
| 20100114026 | Karratt et al. | May 2010 | A1 |
| 20100121167 | McGarraugh | May 2010 | A1 |
| 20100137784 | Cefai et al. | Jun 2010 | A1 |
| 20100145272 | Cefai et al. | Jun 2010 | A1 |
| 20100152658 | Hanson et al. | Jun 2010 | A1 |
| 20100165795 | Elder et al. | Jul 2010 | A1 |
| 20100168538 | Keenan et al. | Jul 2010 | A1 |
| 20100168820 | Maniak et al. | Jul 2010 | A1 |
| 20100174228 | Buckingham et al. | Jul 2010 | A1 |
| 20100174229 | Hsu et al. | Jul 2010 | A1 |
| 20100174266 | Estes | Jul 2010 | A1 |
| 20100179409 | Kamath et al. | Jul 2010 | A1 |
| 20100185183 | Alme et al. | Jul 2010 | A1 |
| 20100211003 | Sundar et al. | Aug 2010 | A1 |
| 20100211005 | Edwards et al. | Aug 2010 | A1 |
| 20100241066 | Hansen et al. | Sep 2010 | A1 |
| 20100249530 | Rankers et al. | Sep 2010 | A1 |
| 20100262117 | Magni et al. | Oct 2010 | A1 |
| 20100262434 | Shaya | Oct 2010 | A1 |
| 20100273738 | Valcke et al. | Oct 2010 | A1 |
| 20100286601 | Yodfat et al. | Nov 2010 | A1 |
| 20100286653 | Kubel et al. | Nov 2010 | A1 |
| 20100298685 | Hayter et al. | Nov 2010 | A1 |
| 20100298765 | Budiman et al. | Nov 2010 | A1 |
| 20100324382 | Cantwell et al. | Dec 2010 | A1 |
| 20100324977 | Dragt | Dec 2010 | A1 |
| 20100325864 | Briones et al. | Dec 2010 | A1 |
| 20110009813 | Rankers | Jan 2011 | A1 |
| 20110015511 | Bousamra et al. | Jan 2011 | A1 |
| 20110021584 | Berggren et al. | Jan 2011 | A1 |
| 20110028817 | Jin et al. | Feb 2011 | A1 |
| 20110040247 | Mandro et al. | Feb 2011 | A1 |
| 20110049394 | De Rochemont | Mar 2011 | A1 |
| 20110054390 | Searle et al. | Mar 2011 | A1 |
| 20110054399 | Chong et al. | Mar 2011 | A1 |
| 20110065224 | Bollman et al. | Mar 2011 | A1 |
| 20110071464 | Palerm | Mar 2011 | A1 |
| 20110071765 | Yodfat et al. | Mar 2011 | A1 |
| 20110098637 | Hill | Apr 2011 | A1 |
| 20110098674 | Vicente et al. | Apr 2011 | A1 |
| 20110105955 | Yudovsky et al. | May 2011 | A1 |
| 20110106050 | Yodfat et al. | May 2011 | A1 |
| 20110118699 | Yodfat et al. | May 2011 | A1 |
| 20110124996 | Reinke et al. | May 2011 | A1 |
| 20110130716 | Estes et al. | Jun 2011 | A1 |
| 20110144586 | Michaud et al. | Jun 2011 | A1 |
| 20110160652 | Yodfat et al. | Jun 2011 | A1 |
| 20110163880 | Halff et al. | Jul 2011 | A1 |
| 20110178472 | Cabiri | Jul 2011 | A1 |
| 20110190694 | Lanier et al. | Aug 2011 | A1 |
| 20110199194 | Waldock et al. | Aug 2011 | A1 |
| 20110202005 | Yodfat et al. | Aug 2011 | A1 |
| 20110218495 | Remde | Sep 2011 | A1 |
| 20110224523 | Budiman | Sep 2011 | A1 |
| 20110230833 | Landman et al. | Sep 2011 | A1 |
| 20110251509 | Beyhan et al. | Oct 2011 | A1 |
| 20110313390 | Roy et al. | Dec 2011 | A1 |
| 20110313680 | Doyle et al. | Dec 2011 | A1 |
| 20110316562 | Cefai et al. | Dec 2011 | A1 |
| 20110319813 | Kamen et al. | Dec 2011 | A1 |
| 20120003935 | Lydon et al. | Jan 2012 | A1 |
| 20120010594 | Holt et al. | Jan 2012 | A1 |
| 20120016304 | Patel et al. | Jan 2012 | A1 |
| 20120029468 | Diperna et al. | Feb 2012 | A1 |
| 20120030393 | Ganesh et al. | Feb 2012 | A1 |
| 20120046606 | Arefieg | Feb 2012 | A1 |
| 20120053556 | Lee | Mar 2012 | A1 |
| 20120065894 | Tubb et al. | Mar 2012 | A1 |
| 20120078067 | Kovatchev et al. | Mar 2012 | A1 |
| 20120078161 | Masterson et al. | Mar 2012 | A1 |
| 20120078181 | Smith et al. | Mar 2012 | A1 |
| 20120101451 | Boit et al. | Apr 2012 | A1 |
| 20120123234 | Atlas et al. | May 2012 | A1 |
| 20120124521 | Guo | May 2012 | A1 |
| 20120150446 | Chang et al. | Jun 2012 | A1 |
| 20120150556 | Galasso et al. | Jun 2012 | A1 |
| 20120172694 | Desborough et al. | Jul 2012 | A1 |
| 20120172802 | Blomquist | Jul 2012 | A1 |
| 20120185267 | Kamen et al. | Jul 2012 | A1 |
| 20120190955 | Rao et al. | Jul 2012 | A1 |
| 20120197207 | Stefanski | Aug 2012 | A1 |
| 20120203085 | Rebec | Aug 2012 | A1 |
| 20120203178 | Tverskoy | Aug 2012 | A1 |
| 20120203467 | Kamath et al. | Aug 2012 | A1 |
| 20120209208 | Stefanski | Aug 2012 | A1 |
| 20120215087 | Cobelli et al. | Aug 2012 | A1 |
| 20120225134 | Komorowski | Sep 2012 | A1 |
| 20120226259 | Yodfat et al. | Sep 2012 | A1 |
| 20120227737 | Mastrototaro et al. | Sep 2012 | A1 |
| 20120232520 | Sloan et al. | Sep 2012 | A1 |
| 20120238851 | Kamen et al. | Sep 2012 | A1 |
| 20120238853 | Arefieg | Sep 2012 | A1 |
| 20120238999 | Estes et al. | Sep 2012 | A1 |
| 20120245448 | Shariati et al. | Sep 2012 | A1 |
| 20120245556 | Kovatchev et al. | Sep 2012 | A1 |
| 20120245855 | Kamath et al. | Sep 2012 | A1 |
| 20120246106 | Atlas et al. | Sep 2012 | A1 |
| 20120250449 | Nakano | Oct 2012 | A1 |
| 20120259191 | Shariati et al. | Oct 2012 | A1 |
| 20120271655 | Knobel et al. | Oct 2012 | A1 |
| 20120277668 | Chawla | Nov 2012 | A1 |
| 20120277723 | Skladnev et al. | Nov 2012 | A1 |
| 20120282111 | Nip et al. | Nov 2012 | A1 |
| 20120283694 | Yodfat et al. | Nov 2012 | A1 |
| 20120289931 | Robinson et al. | Nov 2012 | A1 |
| 20120295550 | Wilson et al. | Nov 2012 | A1 |
| 20120302991 | Blomquist et al. | Nov 2012 | A1 |
| 20120323590 | Udani | Dec 2012 | A1 |
| 20120330270 | Colton | Dec 2012 | A1 |
| 20130030358 | Yodfat et al. | Jan 2013 | A1 |
| 20130046281 | Javitt | Feb 2013 | A1 |
| 20130053818 | Estes | Feb 2013 | A1 |
| 20130053819 | Estes | Feb 2013 | A1 |
| 20130053820 | Estes et al. | Feb 2013 | A1 |
| 20130102867 | Desborough et al. | Apr 2013 | A1 |
| 20130116649 | Breton et al. | May 2013 | A1 |
| 20130138205 | Kushwaha et al. | May 2013 | A1 |
| 20130158503 | Kanderian et al. | Jun 2013 | A1 |
| 20130159456 | Daoud et al. | Jun 2013 | A1 |
| 20130165041 | Bukovjan et al. | Jun 2013 | A1 |
| 20130172695 | Nielsen et al. | Jul 2013 | A1 |
| 20130172710 | Mears et al. | Jul 2013 | A1 |
| 20130178791 | Javitt | Jul 2013 | A1 |
| 20130204186 | Moore et al. | Aug 2013 | A1 |
| 20130204202 | Trombly et al. | Aug 2013 | A1 |
| 20130218126 | Hayter et al. | Aug 2013 | A1 |
| 20130231642 | Doyle et al. | Sep 2013 | A1 |
| 20130237932 | Thueer et al. | Sep 2013 | A1 |
| 20130245545 | Arnold et al. | Sep 2013 | A1 |
| 20130245563 | Mercer et al. | Sep 2013 | A1 |
| 20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
| 20130253284 | Fraier et al. | Sep 2013 | A1 |
| 20130253418 | Kamath et al. | Sep 2013 | A1 |
| 20130253472 | Cabiri | Sep 2013 | A1 |
| 20130261406 | Rebec et al. | Oct 2013 | A1 |
| 20130275139 | Coleman | Oct 2013 | A1 |
| 20130281965 | Kamen et al. | Oct 2013 | A1 |
| 20130296792 | Cabiri | Nov 2013 | A1 |
| 20130296823 | Melker et al. | Nov 2013 | A1 |
| 20130297334 | Galasso et al. | Nov 2013 | A1 |
| 20130298080 | Griffin et al. | Nov 2013 | A1 |
| 20130317753 | Kamen et al. | Nov 2013 | A1 |
| 20130332874 | Rosinko et al. | Dec 2013 | A1 |
| 20130338576 | O'Connor et al. | Dec 2013 | A1 |
| 20130338629 | Agrawal et al. | Dec 2013 | A1 |
| 20130338630 | Agrawal et al. | Dec 2013 | A1 |
| 20130345663 | Agrawal et al. | Dec 2013 | A1 |
| 20130346858 | Neyrinck | Dec 2013 | A1 |
| 20140005633 | Finan | Jan 2014 | A1 |
| 20140018730 | Stephan | Jan 2014 | A1 |
| 20140025015 | Cross et al. | Jan 2014 | A1 |
| 20140031759 | Kouyoumjian et al. | Jan 2014 | A1 |
| 20140032549 | McDaniel et al. | Jan 2014 | A1 |
| 20140039383 | Dobbles et al. | Feb 2014 | A1 |
| 20140052091 | Dobbles et al. | Feb 2014 | A1 |
| 20140052092 | Dobbles et al. | Feb 2014 | A1 |
| 20140052093 | Dobbles et al. | Feb 2014 | A1 |
| 20140052094 | Dobbles et al. | Feb 2014 | A1 |
| 20140052095 | Dobbles et al. | Feb 2014 | A1 |
| 20140066859 | Ogawa et al. | Mar 2014 | A1 |
| 20140066884 | Keenan et al. | Mar 2014 | A1 |
| 20140066885 | Keenan et al. | Mar 2014 | A1 |
| 20140066886 | Roy et al. | Mar 2014 | A1 |
| 20140066887 | Mastrototaro et al. | Mar 2014 | A1 |
| 20140066888 | Parikh et al. | Mar 2014 | A1 |
| 20140066889 | Grosman et al. | Mar 2014 | A1 |
| 20140066890 | Sloan et al. | Mar 2014 | A1 |
| 20140066892 | Keenan et al. | Mar 2014 | A1 |
| 20140074033 | Sonderegger et al. | Mar 2014 | A1 |
| 20140088428 | Yang et al. | Mar 2014 | A1 |
| 20140088557 | Mernoe et al. | Mar 2014 | A1 |
| 20140094766 | Estes et al. | Apr 2014 | A1 |
| 20140107607 | Estes | Apr 2014 | A1 |
| 20140108046 | Echeverria et al. | Apr 2014 | A1 |
| 20140114278 | Dobbles et al. | Apr 2014 | A1 |
| 20140121635 | Hayter | May 2014 | A1 |
| 20140127048 | Diianni et al. | May 2014 | A1 |
| 20140128705 | Mazlish | May 2014 | A1 |
| 20140128803 | Dobbles et al. | May 2014 | A1 |
| 20140128839 | Diianni et al. | May 2014 | A1 |
| 20140129951 | Amin et al. | May 2014 | A1 |
| 20140135880 | Baumgartner et al. | May 2014 | A1 |
| 20140142508 | Diianni et al. | May 2014 | A1 |
| 20140146202 | Boss et al. | May 2014 | A1 |
| 20140171901 | Langsdorf et al. | Jun 2014 | A1 |
| 20140180203 | Budiman et al. | Jun 2014 | A1 |
| 20140180240 | Finan et al. | Jun 2014 | A1 |
| 20140200426 | Taub et al. | Jul 2014 | A1 |
| 20140200559 | Doyle et al. | Jul 2014 | A1 |
| 20140228627 | Soffer et al. | Aug 2014 | A1 |
| 20140228668 | Wakizaka et al. | Aug 2014 | A1 |
| 20140230021 | Birtwhistle et al. | Aug 2014 | A1 |
| 20140235981 | Hayter | Aug 2014 | A1 |
| 20140249500 | Estes | Sep 2014 | A1 |
| 20140276553 | Rosinko et al. | Sep 2014 | A1 |
| 20140276554 | Finan et al. | Sep 2014 | A1 |
| 20140276555 | Morales | Sep 2014 | A1 |
| 20140276556 | Saint et al. | Sep 2014 | A1 |
| 20140276583 | Chen et al. | Sep 2014 | A1 |
| 20140278123 | Prodhom et al. | Sep 2014 | A1 |
| 20140309615 | Mazlish | Oct 2014 | A1 |
| 20140316379 | Sonderegger et al. | Oct 2014 | A1 |
| 20140323959 | Lebel et al. | Oct 2014 | A1 |
| 20140325065 | Birtwhistle et al. | Oct 2014 | A1 |
| 20150018633 | Kovachev et al. | Jan 2015 | A1 |
| 20150025329 | Amarasingham et al. | Jan 2015 | A1 |
| 20150025471 | Enggaard | Jan 2015 | A1 |
| 20150025495 | Peyser | Jan 2015 | A1 |
| 20150025503 | Searle et al. | Jan 2015 | A1 |
| 20150030641 | Anderson et al. | Jan 2015 | A1 |
| 20150041498 | Kakiuchi et al. | Feb 2015 | A1 |
| 20150045737 | Stefanski | Feb 2015 | A1 |
| 20150073337 | Saint et al. | Mar 2015 | A1 |
| 20150080789 | Estes et al. | Mar 2015 | A1 |
| 20150120317 | Mayou et al. | Apr 2015 | A1 |
| 20150120323 | Galasso et al. | Apr 2015 | A1 |
| 20150134265 | Kohlbrecher et al. | May 2015 | A1 |
| 20150134353 | Ferrell et al. | May 2015 | A1 |
| 20150136336 | Huang et al. | May 2015 | A1 |
| 20150148774 | Yao | May 2015 | A1 |
| 20150157794 | Roy et al. | Jun 2015 | A1 |
| 20150164414 | Matthews | Jun 2015 | A1 |
| 20150165119 | Palerm et al. | Jun 2015 | A1 |
| 20150173674 | Hayes et al. | Jun 2015 | A1 |
| 20150193585 | Sunna | Jul 2015 | A1 |
| 20150202386 | Brady et al. | Jul 2015 | A1 |
| 20150205509 | Scriven et al. | Jul 2015 | A1 |
| 20150205511 | Vinna et al. | Jul 2015 | A1 |
| 20150213217 | Amarasingham et al. | Jul 2015 | A1 |
| 20150217051 | Mastrototaro et al. | Aug 2015 | A1 |
| 20150217052 | Keenan et al. | Aug 2015 | A1 |
| 20150217053 | Booth et al. | Aug 2015 | A1 |
| 20150265767 | Vazquez et al. | Sep 2015 | A1 |
| 20150265768 | Vazquez et al. | Sep 2015 | A1 |
| 20150301691 | Qin | Oct 2015 | A1 |
| 20150306314 | Doyle et al. | Oct 2015 | A1 |
| 20150314062 | Blomquist et al. | Nov 2015 | A1 |
| 20150320933 | Estes | Nov 2015 | A1 |
| 20150328402 | Nogueira et al. | Nov 2015 | A1 |
| 20150331995 | Zhao et al. | Nov 2015 | A1 |
| 20150351671 | Vanslyke et al. | Dec 2015 | A1 |
| 20150351672 | Vanslyke et al. | Dec 2015 | A1 |
| 20150351683 | Brauker et al. | Dec 2015 | A1 |
| 20150352282 | Mazlish | Dec 2015 | A1 |
| 20150352283 | Galasso | Dec 2015 | A1 |
| 20150356250 | Polimeni | Dec 2015 | A1 |
| 20150366945 | Greene | Dec 2015 | A1 |
| 20160000998 | Estes | Jan 2016 | A1 |
| 20160015891 | Papiorek | Jan 2016 | A1 |
| 20160019352 | Cohen et al. | Jan 2016 | A1 |
| 20160030669 | Harris et al. | Feb 2016 | A1 |
| 20160038673 | Morales | Feb 2016 | A1 |
| 20160038689 | Lee et al. | Feb 2016 | A1 |
| 20160051749 | Istoc | Feb 2016 | A1 |
| 20160082187 | Schaible et al. | Mar 2016 | A1 |
| 20160082188 | Blomquist et al. | Mar 2016 | A1 |
| 20160089494 | Guerrini | Mar 2016 | A1 |
| 20160158438 | Monirabbasi et al. | Jun 2016 | A1 |
| 20160162662 | Monirabbasi et al. | Jun 2016 | A1 |
| 20160175520 | Palerm et al. | Jun 2016 | A1 |
| 20160213841 | Geismar et al. | Jul 2016 | A1 |
| 20160220181 | Rigoard et al. | Aug 2016 | A1 |
| 20160228641 | Gescheit et al. | Aug 2016 | A1 |
| 20160243318 | Despa et al. | Aug 2016 | A1 |
| 20160256087 | Doyle et al. | Sep 2016 | A1 |
| 20160256629 | Grosman et al. | Sep 2016 | A1 |
| 20160259889 | Murtha et al. | Sep 2016 | A1 |
| 20160287512 | Cooper et al. | Oct 2016 | A1 |
| 20160302054 | Kimura et al. | Oct 2016 | A1 |
| 20160331310 | Kovatchev | Nov 2016 | A1 |
| 20160354543 | Cinar et al. | Dec 2016 | A1 |
| 20170007882 | Werner | Jan 2017 | A1 |
| 20170021096 | Cole et al. | Jan 2017 | A1 |
| 20170049386 | Abraham et al. | Feb 2017 | A1 |
| 20170131887 | Kim et al. | May 2017 | A1 |
| 20170143899 | Gondhalekar et al. | May 2017 | A1 |
| 20170143900 | Rioux et al. | May 2017 | A1 |
| 20170156682 | Doyle et al. | Jun 2017 | A1 |
| 20170173261 | O'Connor et al. | Jun 2017 | A1 |
| 20170182248 | Rosinko | Jun 2017 | A1 |
| 20170188943 | Braig et al. | Jul 2017 | A1 |
| 20170189614 | Mazlish et al. | Jul 2017 | A1 |
| 20170189625 | Cirillo et al. | Jul 2017 | A1 |
| 20170203036 | Mazlish et al. | Jul 2017 | A1 |
| 20170216524 | Haider et al. | Aug 2017 | A1 |
| 20170239415 | Hwang et al. | Aug 2017 | A1 |
| 20170258987 | Caspers | Sep 2017 | A1 |
| 20170281877 | Marlin et al. | Oct 2017 | A1 |
| 20170296746 | Chen et al. | Oct 2017 | A1 |
| 20170311903 | Davis et al. | Nov 2017 | A1 |
| 20170347971 | Davis et al. | Dec 2017 | A1 |
| 20170348482 | Duke et al. | Dec 2017 | A1 |
| 20180036495 | Searle et al. | Feb 2018 | A1 |
| 20180040255 | Freeman et al. | Feb 2018 | A1 |
| 20180075200 | Davis et al. | Mar 2018 | A1 |
| 20180075201 | Davis et al. | Mar 2018 | A1 |
| 20180075202 | Davis et al. | Mar 2018 | A1 |
| 20180092576 | Ambrsio | Apr 2018 | A1 |
| 20180126073 | Wu et al. | May 2018 | A1 |
| 20180169334 | Grosman et al. | Jun 2018 | A1 |
| 20180200434 | Mazlish et al. | Jul 2018 | A1 |
| 20180200438 | Mazlish et al. | Jul 2018 | A1 |
| 20180200441 | Desborough et al. | Jul 2018 | A1 |
| 20180204636 | Edwards et al. | Jul 2018 | A1 |
| 20180277253 | Gondhalekar et al. | Sep 2018 | A1 |
| 20180289891 | Finan et al. | Oct 2018 | A1 |
| 20180296757 | Finan et al. | Oct 2018 | A1 |
| 20180307515 | Meller et al. | Oct 2018 | A1 |
| 20180342317 | Skirble et al. | Nov 2018 | A1 |
| 20180369479 | Hayter et al. | Dec 2018 | A1 |
| 20190076600 | Grosman et al. | Mar 2019 | A1 |
| 20190095052 | De et al. | Mar 2019 | A1 |
| 20190132801 | Kamath et al. | May 2019 | A1 |
| 20190184091 | Sjolund et al. | Jun 2019 | A1 |
| 20190240403 | Palerm et al. | Aug 2019 | A1 |
| 20190290844 | Monirabbasi et al. | Sep 2019 | A1 |
| 20190321545 | Saint | Oct 2019 | A1 |
| 20190336683 | O'Connor et al. | Nov 2019 | A1 |
| 20190336684 | O'Connor et al. | Nov 2019 | A1 |
| 20190348157 | Booth et al. | Nov 2019 | A1 |
| 20190374714 | Rioux et al. | Dec 2019 | A1 |
| 20200001006 | Pizzochero et al. | Jan 2020 | A1 |
| 20200046268 | Patek et al. | Feb 2020 | A1 |
| 20200101222 | Lintereur et al. | Apr 2020 | A1 |
| 20200101223 | Lintereur et al. | Apr 2020 | A1 |
| 20200101225 | O'Connor et al. | Apr 2020 | A1 |
| 20200113515 | O'Connor et al. | Apr 2020 | A1 |
| 20200219625 | Kahlbaugh | Jul 2020 | A1 |
| 20200342974 | Chen et al. | Oct 2020 | A1 |
| 20210050085 | Hayter et al. | Feb 2021 | A1 |
| 20210098105 | Lee et al. | Apr 2021 | A1 |
| 20220023536 | Graham et al. | Jan 2022 | A1 |
| 20220105270 | Doyle et al. | Apr 2022 | A1 |
| 20220126027 | Narayanaswami | Apr 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2015200834 | Mar 2015 | AU |
| 2015301146 | Mar 2017 | AU |
| 1040271 | Oct 1978 | CA |
| 2543545 | May 2005 | CA |
| 3026851 | Feb 2020 | CA |
| 1297140 | May 2001 | CN |
| 1859943 | Nov 2006 | CN |
| 101208699 | Jun 2008 | CN |
| 4200595 | Jul 1993 | DE |
| 19627619 | Jan 1998 | DE |
| 19756872 | Jul 1999 | DE |
| 19912459 | Sep 2000 | DE |
| 10236669 | Feb 2004 | DE |
| 202005012358 | Oct 2005 | DE |
| 200401893 | Dec 2004 | DK |
| 0026056 | Apr 1981 | EP |
| 0062974 | Oct 1982 | EP |
| 0098592 | Jan 1984 | EP |
| 0275213 | Jul 1988 | EP |
| 0341049 | Nov 1989 | EP |
| 0496141 | Jul 1992 | EP |
| 0496305 | Jul 1992 | EP |
| 0549341 | Jun 1993 | EP |
| 0580723 | Feb 1994 | EP |
| 0612004 | Aug 1994 | EP |
| 0721358 | Jul 1996 | EP |
| 0867196 | Sep 1998 | EP |
| 0939451 | Sep 1999 | EP |
| 1045146 | Oct 2000 | EP |
| 1136698 | Sep 2001 | EP |
| 1376759 | Jan 2004 | EP |
| 1177802 | Sep 2004 | EP |
| 1491144 | Dec 2004 | EP |
| 1495775 | Jan 2005 | EP |
| 1527792 | May 2005 | EP |
| 1571582 | Sep 2005 | EP |
| 0801578 | Jul 2006 | EP |
| 1754498 | Feb 2007 | EP |
| 1818664 | Aug 2007 | EP |
| 1824536 | Aug 2007 | EP |
| 1951340 | Aug 2008 | EP |
| 2139382 | Jan 2010 | EP |
| 2397181 | Dec 2011 | EP |
| 2468338 | Jun 2012 | EP |
| 2666520 | Nov 2013 | EP |
| 2695573 | Feb 2014 | EP |
| 2703024 | Mar 2014 | EP |
| 2764881 | Aug 2014 | EP |
| 2830499 | Feb 2015 | EP |
| 2897071 | Jul 2015 | EP |
| 2943149 | Nov 2015 | EP |
| 3177344 | Jun 2017 | EP |
| 3193979 | Jul 2017 | EP |
| 3314548 | May 2018 | EP |
| 3607985 | Feb 2020 | EP |
| 2096275 | Feb 1972 | FR |
| 2585252 | Jan 1987 | FR |
| 0747701 | Apr 1956 | GB |
| 1125897 | Sep 1968 | GB |
| 2218831 | Nov 1989 | GB |
| 2443261 | Apr 2008 | GB |
| 51-125993 | Nov 1976 | JP |
| 02-131777 | May 1990 | JP |
| 09-504974 | May 1997 | JP |
| 11-010036 | Jan 1999 | JP |
| 2000-513974 | Oct 2000 | JP |
| 2002-085556 | Mar 2002 | JP |
| 2002-507459 | Mar 2002 | JP |
| 2002-523149 | Jul 2002 | JP |
| 2003-531691 | Oct 2003 | JP |
| 2004-283378 | Oct 2004 | JP |
| 2005-326943 | Nov 2005 | JP |
| 2007-525276 | Sep 2007 | JP |
| 2008-513142 | May 2008 | JP |
| 2010-502361 | Jan 2010 | JP |
| 2010-524639 | Jul 2010 | JP |
| 2012-527981 | Nov 2012 | JP |
| 2017-516548 | Jun 2017 | JP |
| 2017-525451 | Sep 2017 | JP |
| 2018-153569 | Oct 2018 | JP |
| 2019-525276 | Sep 2019 | JP |
| 200740148 | Oct 2007 | TW |
| M452390 | May 2013 | TW |
| 8606796 | Nov 1986 | WO |
| 9015928 | Dec 1990 | WO |
| 9509021 | Apr 1995 | WO |
| 9721457 | Jun 1997 | WO |
| 9800193 | Jan 1998 | WO |
| 9804301 | Feb 1998 | WO |
| 9811927 | Mar 1998 | WO |
| 9855073 | Dec 1998 | WO |
| 9857683 | Dec 1998 | WO |
| 9907425 | Feb 1999 | WO |
| 9910040 | Mar 1999 | WO |
| 9910049 | Mar 1999 | WO |
| 9921596 | May 1999 | WO |
| 9939118 | Aug 1999 | WO |
| 9948546 | Sep 1999 | WO |
| 9956803 | Nov 1999 | WO |
| 9962576 | Dec 1999 | WO |
| 0030705 | Jun 2000 | WO |
| 0032258 | Jun 2000 | WO |
| 0048112 | Aug 2000 | WO |
| 0154753 | Aug 2001 | WO |
| 0172354 | Oct 2001 | WO |
| 0172360 | Oct 2001 | WO |
| 0178812 | Oct 2001 | WO |
| 0191822 | Dec 2001 | WO |
| 0191833 | Dec 2001 | WO |
| 0215954 | Feb 2002 | WO |
| 0226282 | Apr 2002 | WO |
| 0240083 | May 2002 | WO |
| 0243866 | Jun 2002 | WO |
| 0257627 | Jul 2002 | WO |
| 0268015 | Sep 2002 | WO |
| 0276535 | Oct 2002 | WO |
| 0281012 | Oct 2002 | WO |
| 0282990 | Oct 2002 | WO |
| 0284336 | Oct 2002 | WO |
| 2002100469 | Dec 2002 | WO |
| 0316882 | Feb 2003 | WO |
| 0323728 | Mar 2003 | WO |
| 0326728 | Mar 2003 | WO |
| 0326726 | Apr 2003 | WO |
| 0339362 | May 2003 | WO |
| 0345233 | Jun 2003 | WO |
| 0397133 | Nov 2003 | WO |
| 2003103763 | Dec 2003 | WO |
| 2004041330 | May 2004 | WO |
| 2004043250 | May 2004 | WO |
| 2004056412 | Jul 2004 | WO |
| 2004092715 | Oct 2004 | WO |
| 2004093648 | Nov 2004 | WO |
| 2004110526 | Dec 2004 | WO |
| 2005002652 | Jan 2005 | WO |
| 2005011779 | Feb 2005 | WO |
| 2005011799 | Feb 2005 | WO |
| 2005039673 | May 2005 | WO |
| 2005051170 | Jun 2005 | WO |
| 2005072794 | Aug 2005 | WO |
| 2005072795 | Aug 2005 | WO |
| 2005082436 | Sep 2005 | WO |
| 2005110601 | Nov 2005 | WO |
| 2005113036 | Dec 2005 | WO |
| 2006053007 | May 2006 | WO |
| 2006061354 | Jun 2006 | WO |
| 2006067217 | Jun 2006 | WO |
| 2006075016 | Jul 2006 | WO |
| 2006097453 | Sep 2006 | WO |
| 2006105792 | Oct 2006 | WO |
| 2006105793 | Oct 2006 | WO |
| 2006105794 | Oct 2006 | WO |
| 2007005219 | Jan 2007 | WO |
| 2007056247 | May 2007 | WO |
| 2007056504 | May 2007 | WO |
| 2007056592 | May 2007 | WO |
| 2007064835 | Jun 2007 | WO |
| 2007066152 | Jun 2007 | WO |
| 2007071255 | Jun 2007 | WO |
| 2007078937 | Jul 2007 | WO |
| 2007078992 | Jul 2007 | WO |
| 2007141786 | Dec 2007 | WO |
| 2008016621 | Feb 2008 | WO |
| 2008024810 | Feb 2008 | WO |
| 2008029403 | Mar 2008 | WO |
| 2008073609 | Jun 2008 | WO |
| 2008089184 | Jul 2008 | WO |
| 2008103175 | Aug 2008 | WO |
| 2008133702 | Nov 2008 | WO |
| 2008134146 | Nov 2008 | WO |
| 2009032402 | Mar 2009 | WO |
| 2009035759 | Mar 2009 | WO |
| 2009039203 | Mar 2009 | WO |
| 2009045462 | Apr 2009 | WO |
| 2009049252 | Apr 2009 | WO |
| 2009066287 | May 2009 | WO |
| 2009066288 | May 2009 | WO |
| 2009098648 | Aug 2009 | WO |
| 2009134380 | Nov 2009 | WO |
| 2010022069 | Feb 2010 | WO |
| 2010045460 | Apr 2010 | WO |
| 2010053702 | May 2010 | WO |
| 2010077279 | Jul 2010 | WO |
| 2010097796 | Sep 2010 | WO |
| 2010132077 | Nov 2010 | WO |
| 2010138848 | Dec 2010 | WO |
| 2010139793 | Dec 2010 | WO |
| 2010147659 | Dec 2010 | WO |
| 2011031458 | Mar 2011 | WO |
| 2011075042 | Jun 2011 | WO |
| 2011095483 | Aug 2011 | WO |
| 2011133823 | Oct 2011 | WO |
| 2012045667 | Apr 2012 | WO |
| 2012073032 | Jun 2012 | WO |
| 2012108959 | Aug 2012 | WO |
| 2012134588 | Oct 2012 | WO |
| 2012177353 | Dec 2012 | WO |
| 2012178134 | Dec 2012 | WO |
| 2013050535 | Apr 2013 | WO |
| 2013078200 | May 2013 | WO |
| 2013134486 | Sep 2013 | WO |
| 2013149186 | Oct 2013 | WO |
| 2013177565 | Nov 2013 | WO |
| 2013182321 | Dec 2013 | WO |
| 2014029416 | Feb 2014 | WO |
| 2014035672 | Mar 2014 | WO |
| 2014062399 | Apr 2014 | WO |
| 2014074476 | May 2014 | WO |
| 2014109898 | Jul 2014 | WO |
| 2014110538 | Jul 2014 | WO |
| 2014134459 | Sep 2014 | WO |
| 2014149357 | Sep 2014 | WO |
| 2014172467 | Oct 2014 | WO |
| 2014179774 | Nov 2014 | WO |
| 2014194183 | Dec 2014 | WO |
| 2015056259 | Apr 2015 | WO |
| 2015061493 | Apr 2015 | WO |
| 2015073211 | May 2015 | WO |
| 2015081337 | Jun 2015 | WO |
| 2015117082 | Aug 2015 | WO |
| 2015117854 | Aug 2015 | WO |
| 2015167201 | Nov 2015 | WO |
| 2015177082 | Nov 2015 | WO |
| 2015187366 | Dec 2015 | WO |
| 2015191459 | Dec 2015 | WO |
| 2016004088 | Jan 2016 | WO |
| 2016004210 | Jan 2016 | WO |
| 2016022650 | Feb 2016 | WO |
| 2016041873 | Mar 2016 | WO |
| 2016089702 | Jun 2016 | WO |
| 2016141082 | Sep 2016 | WO |
| 2016161254 | Oct 2016 | WO |
| 2017004278 | Jan 2017 | WO |
| 2017091624 | Jun 2017 | WO |
| 2017105600 | Jun 2017 | WO |
| 2017184988 | Oct 2017 | WO |
| 2017187177 | Nov 2017 | WO |
| 2017205816 | Nov 2017 | WO |
| 2018009614 | Jan 2018 | WO |
| 2018067748 | Apr 2018 | WO |
| 2018120104 | Jul 2018 | WO |
| 2018136799 | Jul 2018 | WO |
| 2018204568 | Nov 2018 | WO |
| 2019077482 | Apr 2019 | WO |
| 2019094440 | May 2019 | WO |
| 2019213493 | Nov 2019 | WO |
| 2019246381 | Dec 2019 | WO |
| 2020081393 | Apr 2020 | WO |
| 2021011738 | Jan 2021 | WO |
| Entry |
|---|
| US 5,954,699 A, 09/1999, Jost et al. (withdrawn) |
| International Preliminary Report on Patentability in Application No. PCT/US2017/013112, dated Jul. 26, 2018, 6 pages. |
| International Search Report and Written Opinion in Application No. PCT/US2017/013112, dated May 15, 2017, 9 pages. |
| Percival et al., “Closed-Loop Control and Advisory Mode Evaluation of an Artificial Pancreatic B Cell: Use of Proportional-Integral-Derivative Equivalent Model-Based Controllers,” J Diabetes Sci Tech 2(4):636-644, Jul. 2008. |
| European Examination Report from European Application No. 17701779.5, dated Sep. 30, 2021, 8 pages. |
| Decision to grant received for European Patent Application No. 14826694.3, mailed on Apr. 4, 2019, 2 pages. |
| European Communication pursuant to Article 94(3) EPC for European Application No. 14826694.3, dated Oct. 12, 2017, 4 pages. |
| Intention to grant received for European Patent Application No. 14826694.3, mailed on Mar. 20, 2019, 4 pages. |
| Intention to grant received for European Patent Application No. 14826694.3, mailed on Oct. 2, 2018, 6 pages. |
| Supplementary European Extended Search Report and Opinion for European Application No. 14826694.3., dated Jul. 1, 2016, 7 pages. |
| “Minimed Inc. Introduces 407C Infusion Pump for General Medication Use” [online]. Business Wire, AllBusiness.com, Aug. 10, 1999 [retrieved on Feb. 28, 2011]. Retrieved from the Internet: <URL: http://www.allbusiness.com/company-activities-management/product-management/6734565-1.html>. |
| “Using the Deltec Cozmo Insulin Pump Correction Bolus Feature” believed to be publicly available before May 5, 2008, pp. 36-41. |
| “Which Insulin Pump is Right for Me?”, Albany Medical Center, Goodman Diabetes Service, Jan. 2006, 4 pages. |
| Accu-Chek Spirit, “Pump Therapy Made for You,” Roche, 2006, 6 pages. |
| Animas Corporation, IR1200 User Guide Manual, pp. 29-31, revised Sep. 2006. |
| Asante Solutions Pearl User Manual, Asante Inc., 2012, 180 pages. |
| Brown et al., “CGM, Pumps, and SMBG.” American Diabetes Association—71st Scientific Sessions, San Diego, CA, Jun. 24-28, 2011, 38 pages. |
| Collins and Lee, “Microfluidic flow transducer based on the measurement of electrical admittance,” Lab Chip, 2004, 4:7-10. |
| Copp et al., “Simultaneous Model Predictive Control and Moving Horizon Estimation for Blood Glucose Regulation in Type 1 Diabetes,” Optim. Control Appl. Meth. 2016, 15 pages. |
| Cox et al. “Prediction of Severe Hypoglycemia.” Diabetes Care, vol. 30, No. 6, Jun. 2007, 4 pages. |
| Dassau et al., “12-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin Alc and Hypoglycemia” Diabetes Care, Dec. 1, 2017, 40(12):1719-26. |
| Debiotech SA; Debiotech reveals its new miniaturized Disposable Insulin Nanopump} for Diabetes therapy (news release); retrieved from the internet: (http://web.archive.org/web/20060822033820/http://www.debiotech.com/news/nw_159.html); 3 pgs.; Apr. 24, 2006. |
| DOCNews; The latest in high-tech and convenient devices; American Diabetes Assoc.; 2(7); retrieved from the internet: (http://web.archive.org/web/20080526162751/http://docnews.diabetesjournals.org/cgi/content/full/2/7/13?); 3 pgs.; Jul. 1, 2005. |
| Duden Deutsches Universaiworterbuch, Dudenveriag, Mannheim, 1989, p. 822. |
| Dumont, “Feedback control for clinicians,” Journal of clinical monitoring and computing, Feb. 1, 2014, 28(1):5-11. |
| Fischer et al., “In Vivo Comparison of Different Algorithms for the Artificial Beta-Cell,” Artificial organs, May 1, 1985, 9(2):173-9. |
| Guarnieri et al.; Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues (abstract only); J Neurosc Meth; 144(2); pp. 147-152; Jun. 2005. |
| Honan, Matthew. “Apple unveils iPhone” Jan. 9, 2007. MacCentral. Accessed Dec. 29, 2011. 2 pages. |
| Insulet Corporation; Innovative New System for Managing Diabetes Receives FDA Clearance; The OmniPod (Registered) Insulin Management System (press release); retrieved from the internet: (http://phx.corporate-ir.net/phoenix.zhtml? c=209336&p=irol-newsArticle_pf&ID=988708&highlight=); 2 pg .; Feb. 1, 2005. |
| Insulet Corporation; OmniPod (Registered) Insulin Management System (quick-start guide); 2 pgs.; (Copyright) 2008. |
| Keith Hynes et al., “DiAs User Interface: A Patient-Centric Interface for Mobile Artificial Pancreas Systems,” J Diabetes Sci Tech 7(6):1416-1426, Nov. 2013. |
| Kovatchev et al., “Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas,” Diabetes Care 37(7):1789-1796, Jul. 2014. |
| Medtronic News Release, “Medtronic Receives FDA Approval for World's First Insulin Pump with Real-time Continuous Glucose Monitoring,” Apr. 13, 2006, 3 pages. |
| OmniPod Insulin Management System—Investor Relations—Press Release, Feb. 1, 2005, http://investors.insulet.com/phoenix.zhtml?c=209336&p=irol-newsA- rticle&ID=988708&highlight= 1 page. |
| OmniPod Quick Start Guide, 2007, 2 pages. |
| Oxford Advanced Learners Dictionary, 4th Ed., Oxford University Press, Oxford, 1989, p. 178. |
| Patent Abstracts of Japan, vol. 1999, No. 4, and JP 11 010036 , Apr. 30, 1999 and Jan. 19, 1999, Toray Ind. Inc. |
| Salzsieder et al., “Estimation of individually adapted control parameters for an artificial beta cell,” Biomed. Biochim. Acta, Jan. 1, 1984, 43(5):585-596. |
| Shiavon et al., “Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump,” Diabetes care, May 1, 2014, 37(5):1216-23. |
| The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Application for Low Glucose Suspend (LGS) Device System. Rockville, MD, Food and Drug Administration, 2011, 59 pages. |
| The Medtronic Diabetes Connection, 2006, 6 pages. |
| Vozeh et al., “Feedback Control Methods for Drug Dosage Optimisation, Concepts, Classifications and Clinical Application,” Clinical pharmacokinetics, Nov. 1, 1985, 10(6):457-76. |
| Walsh et al., “Guidelines for Insulin Dosing in Continuous Subcutaneous Insulin Infusion Using New Formulas from a Retrospective Study of Individuals with Optimal Glucose Levels”, J. Diabetes Science and Technology, vol. 4 Issue 5, Sep. 2010 (8 pages). |
| Walsh et al., “Guidelines for Optimal Bolus Calculator Settings in Adults”, J. Diabetes Science and Technology; vol. 5 Issue 1; Jan. 2011 (7 pages). |
| Xilas Temp Touch, “The latest in high-tech and convenient devices,” DOCNews, vol. 2, No. 7, Jul. 1, 2005, http://docnews.diabetesioumals.ord/cgi/content/full/2/7/13, 3 pages. |
| International Search Report from International Application No. PCT/US06/43599, mailed Mar. 20, 2007, 4 pages. |
| International Written Opinion from International Application No. PCT/US06/43599, mailed Mar. 20, 2007, 6 pages. |
| Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US14/19441, mailed on May 21, 2014, 2 pages. |
| Examination report No. 1 of Australian Application No. 2023203536, mailed Mar. 8, 2024, 3 pages. |
| First Office Action and Search Report of Chinese Patent Application No. 202111284422.2, issued Apr. 25, 2024, 16 pages with English translation. |
| Examination Report of Canadian Patent Application No. 3,009,409, issued Jun. 26, 2024, 3 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20200206421 A1 | Jul 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62278974 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15404442 | Jan 2017 | US |
| Child | 16802753 | US |
